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ABSTRACT 
Single ventricle physiology can result from various congenital heart defects in 
which the patient has only one functional ventricle. Hypoplastic left heart syndrome 
refers to patients born with an underdeveloped left ventricle. A three stage palliation 
strategy is applied over the first several years of life to establish a viable circulation path 
using the one functioning ventricle. Results of the first stage Norwood procedure on 
neonates with hypoplastic left heart syndrome are unsatisfactory with high morbidities 
and mortalities primarily due to high ventricle load and other complications. An early 
second stage Bidirectional Glenn (BDG) procedure is not a suitable option for neonates 
due to their high pulmonary vascular resistance (PVR), which limits pulmonary blood 
flow. Realistic experimental models of these circulations are not well established and 
would be useful for studying the physiological response to surgical decisions on the 
distribution of flows to the various territories, so as to predict clinical hemodynamics and 
guide clinical planning. These would serve well to study novel intervention strategies and 
the effects of known complications at the local and systems-level. This study proved the 
hypothesis that it is possible to model accurately the first and second stage palliation 
circulations using multi-scale in vitro circulation models and to use these models to test 
novel surgical strategies while including the effects of possible complications.  
A multi-scale mock circulatory system (MCS), which couples a lumped parameter 
network model (LPN) of the neonatal circulation with an anatomically accurate three-
dimensional model of the surgical anastomosis site, was built to simulate the 
hemodynamic performance of both the Stage 1 and Stage 2 circulations. A pediatric 
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ventricular assist device was used as the single ventricle and a respiration model was 
applied to the Stage 2 circulation system. Resulting parameters measured were pressure 
and flow rates within the various territories, and systemic oxygen delivery (OD) were 
calculated. 
The Stage 1 and Stage 2 systems were validated by direct comparisons of time-
based and mean pressures and flow rates between the experimental measurements, 
available clinical recordings and/or CFD simulations. Regression and correlation analyses 
and unpaired t-tests showed that there was excellent agreement between the clinical and 
experimental time-based results as measured throughout the circulations (0.60 < 2R < 0.99; 
p > 0.05,   < 5%). 
A novel, potentially alternative surgical strategy for the initial palliation, was 
proposed and was tested, called the assisted bidirectional Glenn (ABG) procedure. The 
approach taps the higher potential energy of the systemic circulation through a systemic 
to caval shunt with nozzle to increase pulmonary blood flow and oxygen delivery within 
a superior cavopulmonary connection. Experimental model was validated against a 
numerical model (0.65 < 2R < 0.97; p > 0.05). The tested results demonstrated the ABG
had two main advantages over the Norwood circulation. First, the flow through the ABG 
shunt is a fraction of the pulmonary flow, reducing the volume overload on the single 
ventricle and improving systemic and coronary perfusion. Second, the ABG should 
provide a more stable source of pulmonary flow, which should reduce thrombotic risk or 
intimal thickening over an mBT shunt. 
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A study to examine the ejector pump effect was conducted. Two parameters were 
investigated: (1) the superior vena cava (SVC) and pulmonary artery (PA) pressure 
difference; and (2) the SVC and PA pressure difference relative to PA flow rate. Results 
validated the hypothesis that an ejector pump advantage can be adopted in a superior 
cavo-pulmonary circulation, where the low-energy pulmonary blood flow can be assisted 
by an additional source of high energy flow from the systemic circulation. But the ejector 
pump effect produced by the current nozzle designs was not strong. 
Parametric study includes nozzle size, placement, and nozzle shape was 
conducted. Results shown that nozzle to shunt diameter ratio   had the most important 
effects on the ABG performance. As β increased, pulmonary artery flow rate and 
systemic oxygen delivery increased. A suggested β value falls between 0.48 and 0.72. 
The study showed that a bigger β produced a smaller resistance value. The shape of the 
nozzle did not change the resistance value. The effects of shunt angle, nozzle placement 
and nozzle shape on the ABG circulation were not statistical significant. 
The aortic coarctation study showed that the aortic coarctation could have an 
effect on the ABG circulation. The coarctation index (CoI) around 0.5 was found to be 
the transition point between no effects (CoI > 0.5) and discernible effects on the ABG 
circulation. These effects include changes in pulmonary to systemic flow distribution. 
In summary, this research verified and validated an in vitro mock circulatory 
system (MCS) for Stage 1 and Stage 2 circulations. The system was used to assess a 
novel conceptual surgery option named the ABG. Parametric studies were conducted to 
give guidance on designing the important element for the ABG: the shunt (nozzle) 
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connecting the SVC and systemic circulation. The performance of the ABG under one 
unhealthy condition, namely, aortic coarctation was assessed.  
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Hypoplastic Left Heart Syndrome 
Background of HLHS 
Hypoplastic left heart syndrome (HLHS) refers to a congenital heart condition in 
which the left ventricle is underdeveloped and unable to perform its function. It was 
initially termed hypoplasia of the aortic tract complex by Lev in 1952 [1]. HLHS is 
reported to occur in about 4 of every 10,000 live births [1]. The main syndrome of HLHS 
patients includes a not fully developed left ventricle, aorta, and aortic arch, as well as 
mitral atresia or stenosis. The physiology structure is depicted in Figure 1.1. The left 
ventricle is unable to support the systemic circulation [2] and the remaining single 
functioning ventricle must become the work pump for both the systemic circulation and 
pulmonary circulation. At birth, a patent ductus arteriosus is often the only pathway 
through which blood can reach the body from the heart. Over the first days of life, the 
ductus arteriosus normally closes and the blood supply to the body diminishes. This 
single ventricle condition is universally fatal without intervention.  
Currently, there are two options for treating HLHS: primary cardiac 
transplantation or a series of staged palliations using a single ventricle strategy [3, 4]. The 
surgical choice is dependent on the preference of the institution and its experience [3] and 
a patient’s physiological status. The transplant option is highly limited by the few 
newborn organs available, the need for continued anti-rejection therapy, and the limited 
lifespan of the transplanted organ. The more common functional single ventricular 
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palliation strategy typically consists of three stages of operations. The first stage (Stage 1) 
of palliation, referred to as the Norwood operation, is performed shortly after birth. The 
second stage (Stage 2), either a bidirectional Glenn operation or a hemi-Fontan operation, 
is usually undertaken at 6 to 8 months of age. The third stage (Stage 3) is the Fontan 
operation, which is usually performed between the ages of 18 months and 4 years. The 
three stages collectively are referred to as the Fontan conversion. 
 
Early Treatment Options for HLHS 
 
Surgical Stage 1 Procedures 
 
 
Figure 1.1: Schematic of HLHS physiology. Blue arrows represent systemic venous 
(deoxygenated) blood, the red arrow oxygenated blood returning from the lungs, and purple arrows 
mixed blood. Ao, aorta; IVC, inferior vena cava;  LPA, left pulmonary artery; PV, pulmonary 





The Norwood operation is named after William Norwood who first proposed the 
surgery option in 1980 [5]. The goals of the Norwood operation include (1) to provide 
unobstructed systemic blood flow through a reconstructed neoaortic arch; (2) to control 
pulmonary blood flow with a shunt so that the pulmonary arterial bed will develop 
normally; and (3) to reproduce communication between the atria by a complete atrial 
septectomy [6, 7]. The first shunt, named the classic Blalock Taussig (BT) shunt, was 
introduced by Blalock and Taussig in 1945 for patients with tetralogy of Fallot [8]. The 
classic BT shunt is a direct connection between the transected subclavian artery or the 
innominate artery and the pulmonary artery. It does not require the use of prosthetic 
material but requires the sacrifice of the subclavian or innominate artery [9]. The main 
disadvantages of BT shunts include long operative dissection time, phrenic nerve injury, 
technical difficulties during takedown and possible arm ischaemia [10]. Based on the 
understanding of BT shunt, a modified BT shunt (mBTS) is a man-made graft inserted 
between the subclavian or innominate artery and pulmonary arteries (Figure 1.2, left 
figure). The mBTS circulation is characterized by high pulse pressure and diastolic runoff. 
Coronary flow is produced mainly during diastole and diastolic runoff to the shunt 
reduces coronary circulation perfusion. This ‘coronary steal’ can result in myocardial 
ischemia and circulatory instability, which may lead to deaths for Norwood patients [11]. 
The man-made shunt is prone to thrombosis, a life-threatening situation.  
There are surgical alternatives to the mBTS. One surgical variation consists of 
inserting a conduit between the right ventricle and a pulmonary artery and known as the 
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Sano shunt or ‘right ventricle-pulmonary artery shunt (RVPA)’ as proposed by Sano and 
colleagues [7]. Figure 1.2 illustrates the two most common used types of Norwood 
procedures. The left figure shows an mBTS connected to the aorta (AO) and pulmonary 
artery (PA), while the right figure shows a Sano shunt. Other available Stage 1 surgery 
options include a Central Shunt (CS, which is a shunt between the ascending aorta and 
main pulmonary artery), Waterston and Potts shunt and a hybrid Norwood surgery [12].  
Studies found that hemodynamic performances of different surgery options were 
different. Lagana and colleagues did a comparison study of coronary and pulmonary 
blood flow between mBTS and CS based Norwood circulations using a multi-scale CFD 
model [13]. The results demonstrated that CS had higher cardiac output (CO) and shunt 
flow rate. Also, the CS favored fusion to the right lung while the mBTS favored the left 
lung. Migliavacca et al. compared multi-scale computational simulation results and 
clinical data of Norwood operation (CS and mBTS based) and Sano operation to validate 
the functionality of a multi-scale method [14] and found that the Sano shunt based 
circulation would produce the minimum back flow in the shunt. Bove et al. applied the 
same model and investigated how the Norwood circulation reacted to the mBTS and the 
Sano shunts[15]. The results demonstrated that the key advantage of the Sano shunt 
compared with mBTS was that the Sano shunt could reduce the diastolic run-off of the 
systemic circulation and was able to achieve greater hemodynamic stability. The main 
disadvantage of the Sano shunt was that it required a ventriculotomy, a medical 
procedure in which a portion of a patient's one healthy ventricle was resected. This could 
introduce negative effects on right ventricular function, arrhythmias or aneurysm 
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formation related to the ventriculotomy. Other disadvantages included extra volume load 
produced by regurgitation from the nonvalved Sano shunt, impairment growth of the 
pulmonary artery and demand for an earlier Stage 2 palliation [16]. Hsia et al. developed 
a mathematical model to explore the advantages of a hybrid Stage 1 surgery, which 
combined bilateral pulmonary artery banding with arterial duct stenting, compared with 
Norwood surgery with an mBTS or a right Sano shunt. The simulation showed that a 
hybrid Stage 1 palliation might provide lower systemic and cerebral oxygen deliveries 
[17]. Other advantages of this hybrid Stage 1 surgery included postponing the 
complicated reconstruction to an older age when patient is stronger and more tolerant to 
the operative insults, such as circulatory arrest [18].  
For all the Stage 1 palliation options, the shunt must be sized both to regulate the 
amount of pulmonary to systemic blood flow and to reduce pressure between circulations. 
Several questions should be answered for the shunt design.  
First, what is the relationship between the shunt flow and shunt pressure. 
Migliavacca et al. investigated the shunt flow and pressure relationship using a finite 
element method under pulsatile and steady conditions [13]. The relationship could be 
used to help design the shunt inserted. The same model was used to explore the technique 
of extracting shunt flow rate from Doppler measurements [19]. In 2001, Pennati et al. 
evaluated how the anastomotic distensibility and restrictions due to suture presence affect 
the shunt pressure-flow relationship of the anastomoses using a steady flow in vitro 
circuit [20]. An early in vitro study involved the determination of the relationship 
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between Doppler-based pressure gradient and directly measured pressure gradient in the 
mBTS by Tacy and colleagues [21]. 
Second, what is the best design of the shunt, including the shunt diameter and the 
shunt angle. Difficulties in sizing the shunt to achieve an acceptable Qp/Qs (pulmonary 
flow to systemic flow) balance and the lack of growth potential leading to changes in the 
physiological balance with time, and risk of thrombosis with catastrophic consequences 
all must be considered. Song and colleagues found the 5-mm shunt produced the least 
energy loss, but higher wall shear stress compared with 4-mm and 3-mm shunts [22]. 
Sant’Anna and colleagues computed shunt diameter and anastomosis angle effect on a 
Norwood circulation using patient specific shunts [23] and found that the shunt diameter 
played the most important role and an angle between 60 to 90 degrees yield a favorable 
pulmonary blood flow distribution. Waniewski et al. investigated how shear stress and 
wall shear stress on the inserted shunt effect on graft clotting and pulmonary stenosis 
formation using a computational fluid model [24]. Kitagawa and the colleagues 
conducted hydrodynamic experiments (in vitro) to optimize the size and the construction 
of a SP arterial shunt to get suitable pulmonary flow in the Norwood circulation [25]. He 
suggested the suitable diameter of the shunt lie between 3.0 to 3.5 mm. In 2001, 
Migliavacca et al. developed an LPN mathematical model of the Norwood circulation to 
study how the global hemodynamic properties respond to shunt size, vascular resistance 
and heart rate for Stage 1 circulation [26]. In this shunt performance assessment study, 
main findings included that a larger shunt size will harvest a greater pulmonary perfusion 
proportion of the cardiac output. In 2012, Moghadam et al. evaluated the effect of shunt 
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choice of the Norwood circulation on pulmonary and cerebral perfusion and found that 
the shunt size and position could both influence the systemic and coronary oxygen 
deliveries [27]. 
Third, what is the best ratio of Qp/Qs for the Norwood circulation. The Qp/Qs is 
an important parameter to influence the performance of the Norwood circulation. Its 
value is related to the systemic oxygen delivery (OD). In 1994, Barnea et al. reported the 
first mathematical model to simulate the Norwood circulation [28] and investigated the 
relationship between Qp/Qs and the arterial oxygen delivery (OD) for different values of 
cardiac output (CO) and pulmonary venous oxygen saturation. The main finding of the 
study was that systemic oxygen value moved initially to a maximum value, then 
decreased as Qp/Qs ratio increased. The group used the same model to explore the 
oxygen delivery relationship with systemic arterial and venous oxygen saturation, 
arteriovenous oxygen difference and Qp/Qs [29]. This study implied that an appropriate 
Qp/Qs was important. Migliavacca et al. found that a pulmonary to systemic flow ratio 
close to unity produced better systemic oxygen delivery in all physiological states 
(vascular resistance and heart rate) and shunts [26]. But the model had several limitations. 
First, the model was analytical in nature and did not simulate a model of the local fluid 
dynamics. Second, the heart model applied was a steady state approximation, which 
could not represent realistic pulsatile heart properties. 
In summary, the studies have provided useful information on answering the three 
questions. But different studies may draw different conclusions. A reliable mock 




Due to complexities with this delicate physiology, the heterogenous nature of the 
patient pool and the challenges with patient management, outcomes following the 
Norwood procedure remain unsatisfactory with high morbidity and mortality rates. 
Ventricular work load is high as the healthy single ventricle must simultaneously provide 
blood flow to the systemic and pulmonary circulations. According to the clinical record, 
approximately 97% of neonates reached a subsequent state by 18 months after the 
Norwood operation, consisting of death (37%), cavopulmonary shunt conversion or Stage 
2 operation (58%), or some other state (2%, cardiac transplantation, biventricular repair, 
or conversion by a Stage 3 Fontan operation) [30].  
 
Surgical Stage 2 Procedures 
 
Figure 1.2: The Norwood procedure for HLHS, two types of surgeries based on the way the 
pulmonary arteries are connected.  Left: The classical procedure with a systemic pulmonary 
artery shunt. Right: Modification of a RV-PA shunt. Ao, aorta; IVC, inferior vena cava; LPA, left 
pulmonary artery; PV, pulmonary valve; PA, pulmonary artery; RPA, right pulmonary artery; 
RV, right ventricle; SVC, superior vena cava; TV, tricuspid valve[2]. 
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In the Stage 2 operation, as shown in Figure 1.3, the previously implanted shunt 
in Stage 1 is removed and the superior vena cava (SVC) is connected to the pulmonary 
artery. The Stage 2 surgery is a transitional procedure in multistage palliation of HLHS. 
The fundamental purpose of Stage 2 surgery is to relieve the volume load on the single 
ventricle and provide a controlled source of low-pressure pulmonary blood flow. It may 
reduce the deleterious sequence of chronic hypoxemia, which shows an abnormally low 
oxygen in the blood, and long-term ventricular overload, thus yielding a more suitable 
Fontan candidate [31].  
There are two options of Stage 2 operation, the bidirectional Glenn procedure 
(BDG) and the hemi-Fontan procedure (HFP). In the BDG procedure, the SVC is 
connected with the undivided pulmonary arteries and the cardiac end of the SVC is 
closed. BDG is normally straightforward and commonly does not involve augmentation 
of the central pulmonary arteries. Moreover, it does not offer an established connection 
for the inferior vena cava (IVC) at the time of the Fontan operation. In the HFP procedure, 
the central pulmonary arteries are augmented without dividing the SVC. The blood from 
IVC will not be allowed to flow into pulmonary arteries by means of a temporary intra-
atrial patch [32]. The anastomosis part connecting SVC and pulmonary simplifies the 
subsequent lateral tunnel Fontan surgery by avoiding the need for extra dissection that 




In a numerical study, Bove et al. showed that there was no significant 
hemodynamic differences between the BDG and hemi-Fontan [33]. Troianowski et al. 
simulated five BDG circulations, each with patient specific 3D BCPA models and 
boundary conditions derived from direct clinical measurement data. The results 
demonstrated differences among patients, especially in the 3D flow distributions, 
strengthening the importance of patient-specific simulations [34]. Kung et al. developed a 
multi-scale numerical model to simulate a virtual Stage 2 (hemi-Fontan) surgery based on 
preoperative clinical data and demonstrated that the same surgery performed on different 
patients can lead to different hemodynamic properties due to physiological differences 
 
Figure 1.3: Bidirectional Glenn surgery: the cavopulmonary shunt. Ao, aorta; IVC, inferior 
vena cava;  LPA, left pulmonary artery; PV, pulmonary valve; RPA, right pulmonary 
artery; RV, right ventricle; SVC, superior vena cava; TV, tricuspid valve[2]. 
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[35]. Pekkan et al. used the Particle Image Velocimetry (PIV) technique in an in vitro 
model to investigate the local hemodynamic differences as compared with CFD results 
between the hemi-Fontan and Glenn [36]. The study found that the Glenn was 
hemodynamically more efficient with a lower power loss as compared with hemi-Fontan. 
The results were contradictive to the conclusions given by Bove et al.[33] and suggested 
that a more reliable tool was needed to study the complex Stage 2 circulation. 
The outcomes of the Stage 2 procedure compared with the Stage 1 procedure are 
far better. Current results of Stage 2 palliation are satisfactory with mortality rates 
ranging from 0% to 8% among different institution reports [37, 38]. Median arterial 
oxygen saturation is also improved from 79% to 84% [38]. But past experiences with 
neonatal or early Glenn procedures were unsatisfactory. Hence, the current use of Stage 1 
procedures. In an initial report of outcomes following the BDG surgery in 537 patients, 
the highest mortality (over 90%) occurred when the SVC-PA circulation was placed in 
patients less than one month of age [39]. The main causes of death were primarily due to 
inadequate pulmonary blood flow and in some cases, SVC syndrome [39], an obstruction 
of blood flow through the superior vena cava (SVC). Other anecdotal attempts with early 
BDG surgery have also reported similar unsatisfying outcomes [40-42]. The high 
pulmonary vascular resistance (PVR) in neonates is the main cause for the unsatisfying 
results. As its name implies, PVR is a measure of the resistance to blood flow through the 
pulmonary vasculature and it generally decreases as the infant grows. Pennati et al. 
developed a mathematical model to investigate how the local bidirectional cava 
pulmonary anastomosis (BCPA) hemodynamics responding to different PVR values. The 
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results showed that left pulmonary artery (LPA) and right pulmonary artery (RPA) 
pressures were sensitive to PVR values [43]. Guadagni et al. used the LPN model 
coupled with a 3D hemi-Fontan anastomosis model to find that both flow distribution 
into the lungs and energy dissipation after the hemi-Fontan procedure are only slightly 
influenced by the pulmonary arteriolar resistance [44]. Appropriate pulmonary artery size 
and architecture, PVR value, and the function of the atrioventricular valves and systemic 
ventricle determine whether and when the second stage palliation is feasible. The Stage 2 
performance is highly related to the patient’s PVR value. In light of clinical experiences, 
a patient value of PVR indexed to body surface area (BSA) of iPVR < 2 to 3 WU-m2 is 
considered to be suitable for Stage 2  palliation, where 1 WU = 1 mm Hg/Lpm (Liter per 
minute). A typical value of  iPVR in neonates may be 7.0 to 12.0 WU-𝑚2 [26]. 
 
Aortic Coarctation 
Clinical studies demonstrate that a high number of patients after Norwood surgery 
need reintervention of the neoaorta due to recurrence of an aortic coarctation (CoA) [45]. 
CoA is defined as the narrowing of the aortic isthmus and HLHS is always related with 
CoA in juxtaposition with the arterial duct [46]. CoA incidence after the Norwood 
surgery is between 11% and 37% [47, 48].   
Due to the most left-sided obstructive lesions, CoA occurs more in males than in 
females with a male to female ratio varying from 1.27-1.74 [49]. Machii et al. suggests 
that CoA in the preductal position in HLHS is caused by the extension of the ductal tissue 
[50]. Sheikh et al. conclude that: (1) a genetic component of CoA has been found in the 
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Turner XO syndrome, in which about 35% of patients are affected; (2) the patient-
specific aortic morphology also has influence on CoA formation [49]. Surgically excised 
specimens of aortic coarctation demonstrate cystic medial necrosis of varying degrees 
with frequent extension beyond the level of the coarctation. A drawing of CoA is shown 
in Figure 1.4 providing an idea of the position and shape of CoA within the aortic. 
Detection and accurate estimation of coarctation severity are of importance to 
successfully predict long-term outcomes and make suitable treatment options. Clinical 
techniques currently used include measurement of systolic blood pressure gradient across 
the coarctation, chest radiography, Doppler echocardiography and catheter angiography 
[51-53]. These techniques have several limitations and may not provide accurate 
information of coarctation [54]. Figliola et al. developed an in vitro system to assess the 
accuracy of clinical Doppler predictions of coarctation of variable degrees in the 
Norwood circulation [55]. The system was also applied to measurements of Giardini and 
Tacy to study the pressure recovery of CoA to explain Doppler overestimation of 
invasive pressure gradient across segmental vascular stenosis [81]. They explained that 
significant segmental stenosis is associated with significant underestimation of the actual 
pressure gradient due to viscous losses [56]. Keshavarz-Mtamed et al. discussed two flow 
independent parameters, coarctation Doppler velocity index and coarctation effective 
orifice area, to describe severity of coarctation [57]. Biglino et al. experimentally 
validated a computational model of the Norwood circulation with CoA [58]. Itu et al. 
validated their numerical model by comparing four patient specific multi-scale method 
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simulation results to in vivo measurements. The results showed a mean absolute error of 
less than 2 mmHg of pressure-drop across the coarctation in the 4 patients [59]. 
 
Figure 1.4: Coarctation of the Aorta (Downloaded on 10/15/2015 from http://www.chd-uk.co.uk/) 
CoA does not have significant effect on early mortality for Norwood surgery 
patients [60]. But long-term results demonstrate that CoA is a significant problem after 
Norwood surgery, despite the modification of the neoaorta by patch augmentation. CoA 
should be treated seriously, perhaps even for mild coarctation, in order to avoid being 
developed to high-risk situations but the necessary timing of interventions remains 
unclear as intervention has its own risks [61]. Using a 3D CFD model, Olivieri et al. 
revealed that flow in native and surgically repaired aortic arches to correlate respective 
hemodynamics indices with late morbidity incidence [62]. Wall shear stress (WSS) was 
found to be located at varying locations in different morphological models. The finding 
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may transfer a message that varied patterns and locations of WSS in abnormal arch 
remodeling have an effect on clinical vascular dysfunction.  
Severe coarctation can decrease blood flow to the lower body circulation and 
increase aortic pressure. Menon and collaborators compared in vivo (rabbit) test results 
and numerical results to investigate mechanical contributions to mechanisms of morbidity 
in CoA and found that CoA could increase diastolic and mean blood pressure [63]. CoA 
also affects the balance between pulmonary and systemic circulation flow. The main 
damage brought by CoA is the deterioration of ventricle function. CoA can cause 
anomalies of other parts, such as: bicuspid aortic valve, tubular hypoplasia, abnormal 
communication, left ventricle outflow obstruction and positional anomalies [64]. Stenting 
is an invasive alternative to surgery for coarctation treatment [65]. Concern about this 
surgery is that the stent-induced aortic stiffness may increase the cardiac workload and 
blood pressure. But Coogan et al. used a multi-scale model including a patient specific 
coarctation model to find that coarctation stenting may not affect cardiac work to any 
significant degree [66]. This might be explained by that the coarctation for this stenting 
was not strong enough to influence the hemodynamics. It implied that studies, which 
quantifying the coarctation severity where palpable hemodynamic change happened, 
were in need. 
An understanding of how the Norwood circulation or its alternatives globally and 
locally respond to the CoA is needed to provide guidance for the appropriate intervention 
time. Interventional data are difficult to obtain clinically due to the risk to patients. 
Fortunately, advances in engineering methods are aiding the design of improved in vitro 
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models to study CoA. For example, rapid prototype technology now can make accurate 
anatomical reproductions of an altered aortic construction based on clinical imaging data 
and measurement advances provide the physiological parameters needed for patient-
specific studies. Biglino and coworkers built an in vitro multi-scale mock circulatory 
system to reproduce the hemodynamics of post-Norwood surgery and tested patient-
specific anatomies aimed at investigating the effect of CoA [67]. The system successfully 
reproduced physiologic pressures and showed that large pressure drops could be caused 
by CoA. Arzani and colleagues compared numerical predictions of turbulence intensity 
with in vivo measurement in an CoA [68] and showed reasonable agreement. Other 
studies have shown the feasibility to investigate CoA effects [69, 70].  
In conclusion, current experimental and computational techniques provide reliable 
and powerful tools to investigate CoA. Information on when interventional treatment is 
needed for CoA in single ventricle patients. 
 
Modeling Approaches of Cardiovascular Hemodynamics 
There are various approaches available in the engineering field to study 
cardiovascular hemodynamics. Fluid dynamics in large vessels can be represented by 
non-linear partial differential equations of mass and momentum conservation, such as the 
Navier-Stokes equations (NSE). Analytical models reduce the Navier-Stokes equations to 
a form that can be solved analytically for simple cases with boundary conditions properly 
set [12]. Three-dimensional (3D) computational fluid dynamics (CFD) models solve the 
NSE numerically and are used to investigate the hemodynamic properties in specific 
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portions of the cardiovascular system, but it remains impractical to develop a 3D model 
of the entire circulation. CFD models are limited to the boundary conditions applied to 
their inflow and outflow surfaces. Traditionally, bio-fluid CFD models impose some flow 
or pressure waveform at the boundaries of an isolated 3D flow model and solve. Unless 
some means is provided for the local 3D model to dynamically interact with the rest of 
the circulation, systems-level response cannot be predicted.  
The desire to better understand systems-level circulation behavior lead to the 
development of zero dimensional (0D) lumped parameter network (LPN) models of the 
circulation. These provide pressure and flow rate information throughout the circulation 
(systems-level) but cannot provide local hemodynamics or model accurately surgical 
particulars. Multi-scale CFD models were later developed to combine the systems-level 
information of the LPN with the local 3D capabilities of CFD. In multi-scale approaches, 
0D LPN models are coupled dynamically to the inflow and outflow boundaries of a 3D 
CFD model to iteratively provide appropriate time-based boundary condition information.  
 
Lumped Parameter Models  Snyder and Rideout [71] gave a comprehensive 
introduction on how to describe an LPN hydraulic circulation loop. Like an electric 
circuit, the pressure and flow are analogous to voltage and current, viscous and inertial 
properties of blood are analogous to resistors and inductors, respectively, and the 
elasticity of blood vessels are modeled by capacitors. Flow, which is analogous to current, 
is driven by pressure differences, which are analogous to voltage differences. Time based 
capacitors and diodes are applied to model heart contraction and unidirectional flow. 
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These elements translate to a system of ordinary differential equations based on 
resistance (R), capacitance (C) and inductance (L) as driven by pressure differences. The 
solution provides the nodal pressures and flows within the whole circuit. LPN is useful to 
model both the global pulmonary vascular resistance and systemic venous resistance, and 
the local arteries and veins of the circulation. These models can be tailored to patient 
specific values using clinical data, when available. The major limitation of an LPN model 
is that it cannot investigate the local flow dynamics or introduce specific anatomical 
features. Also, pressure wave propagation effects are lost. 
An important part of an LPN models is accurately assigning the elemental (R-C-L) 
values. Clinical measurements of pressures, flows and velocities lead to assignment of 
impedance values in each branch. Main measurement techniques include magnetic 
resonance, cardiac catheterization, and echo-Doppler measurements [72]. Generic 
population-based values have been arrived at over the years for generalized studies (eg. 
[73, 74]). Baretta et al. gave several examples on how to use clinical data to calculate 
LPN parameters [75]. For example, the right pulmonary vascular resistance (PVR) is 
equal to the measured clinical superior vena cava (SVC) pressure minus the atrium 
pressure divided by the right pulmonary flow rate.  
Because clinical measurements can be invasive, there are many situations in 
which patient-specific information will be unavailable or information limited. Under this 
situation, generic values are used wherever clinical information is missing. The effects of 
patient body surface area (BSA) on the generic LPN elemental values are accounted for 
by the application of allometric equations as shown in equations 1-1, where LPN 
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parameters are scaled according to proper powers of the BSA specific for the various 







Here x  and Ox  are the vascular and heart parameters (R, C, L) for the patient BSA and 
for a reference body surface area,
OBSA , respectively. The value Ox  corresponds to an 
adult with BSA of 1.8 m2, as reported by Snyder and Rideout [77].The exponent b is the 
‘scaling factor’ describing the body surface area effect. The suggested values of b for 
difference branches are listed by Baretta et al. [75].  
 
Multi-scale Models    Formaggia et al. first proposed the approach of coupling a 3D 
model with an LPN model [78] and Quarteroni and Veneziani conducted a well-posed 
analysis of this method [60]. Figure 1.5 is an example of a multi-scale model of the Stage 
2 circulation [35].The aim of coupling a 3D domain with a 0D model (LPN) is to provide 
the two sub-domains with accurate boundary conditions. Boundary conditions are 
essential for properly predicting the hemodynamics inside the targeted investigated 
system. In particular for patient-specific models, boundary conditions are applied to 
mimic the valuable available clinical data. In a multiple-inflow/outflow 3D model, the 
flow distribution is determined solely by the outlet resistance in the branches of the 
domain if zero or equal pressures are used at all the outlets [79]. In situations such as the 
Norwood circulation, inlet flows can usually be measured but outlet flows in the 




boundary conditions with a 3D model can be used to predict the global system response 
for changes in physiological alterations, surgery-based construction, and portions of 
downstream or upstream of the 3D model. The 0D models cannot provide spatial 
variables. In contrast, a 0D model coupled with a 3D model can provide the information 
on local hemodynamics, including spatial and time dependent pressures, flow rates, wall 
shear stress (WSS) and energy loss. The iterative interaction of the two subsystems is that 
3D domain provides the 0D model with flow rates at the interface, while the 0D model 




The LPN concept guided the development of in vitro mock circulatory systems 
(MCS) for representing the compliance and resistive properties of the circulation [80]. In 
a multi-scale in vitro model, a hydraulic analog of the LPN is connected to the 
inflow/outflow points of a 3D test section to provide appropriate time-dependent 
boundary conditions.  
Compared with a numerical multi-scale model, an in vitro multi-scale model is 
generally contracted to a reduced LPN model having fewer elemental values within each 
 
Figure 1.5: Full lumped parameter network model coupled with 3D phantom of Stage 2 [36]. 
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branch. This is achieved by applying least-squares impedance matching with Thevenin 
equivalent circuit analysis to the original LPN model. The reasons are that (1) it is 
practical to adjust only a limited number of physical R-C-L elements, and, (2) the 
addition of each physical element can add a small artificial inertance beyond the 
physiological model. For example, a numerical LPN may have over 50 adjustable 
elements and the experimental model may reduce this to fewer than half or less, usually 
by combining proximate resistors and capacitors into equivalent values. The reduced 
number of elements does limit higher order frequency response of the experimental 
model. However, the reduced model method has been validated through excellent 
matches both in terms of mean and time-based pressure and flow rate values between 
experimental results and clinical data as reported in several single ventricle circulation in 
vitro studies [67, 81, 74, 82, 83].  
 
Respiration Modeling In the Univentricular Circulation   As there is no explicit 
indication that respiration impacts any clinical complications in the Stage 1 and the Stage 
2 circulations, previous models of Stage 1 and Stage 2 have ignored respiration and 
thereby have neglected its effects. However, respiration effects on hemodynamics and 
clinical outcomes on the Stage 3 circulation have been documented by Hsia et al [84]and 
Vukicevic et al [82, 74] and a few other studies have modeled respiration effects in the 
Stage 3 Fontan circulation [85, 86, 84]. The function of the respiration system model was 
validated against clinical data [74, 82]. The experiments recapitulated the clinical 
observations that respiration increased antegrade flow towards the heart during 
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inspiration and decreased the flow during expiration, including the possibility of hepatic 
venous and IVC flow reversal [74]. The validated respiration modeling approach can be 
used in a Stage 2 system to impose respiration influences. 
Current results imply that respiration has a time-based influence on IVC, hepatic 
vein (HV) and pulmonary artery flows and pressures within the Stage 3 circulation. 
Respiration effects on Stage 1 and Stage 2 are not clear but respiration is apparent in 
some clinical flow and pressure signals. 
 
Concept of the Assisted Bidirectional Glenn (ABG)  
The Norwood surgery is associated with high mortality and morbidity due to a 
number of drawbacks. The new circulation, created by the implanted shunt, may not keep 
the blood flows to the pulmonary circulation and systemic circulation branches balanced. 
As discussed earlier, outcomes following the Norwood procedure remain unsatisfactory. 
The BDG or hemi-Fontan Stage 2 surgery can provide a more stable source of 
pulmonary blood flow, reduce ventricular workload, and reduce thrombotic risk with 
excellent survival rates. However, the Stage 2 palliation is unsuitable for neonates 
because the high pulmonary resistance of the neonatal circulation limits pulmonary blood 
flow in this circulation. The major causes of death include inadequate pulmonary blood 
flow, which is a consequence of the high PVR in neonates. 
Under this background, Esmaily-Moghadam et al. and Zhou et al. have discussed 
a novel initial palliation option called the Assisted Bidirectional Glenn (ABG) [83, 84]. 
Figure 1.6 illustrates the comparison between the Norwood, the BDG and the ABG 
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circulations. The ABG circulation is a hybrid of the Norwood circulation and the Glenn 
circulation. In the ABG, a reasonably designed shunt would be inserted between the 
systemic circulation and the SVC, which would be connected to the pulmonary artery in 
the manner of a standard Stage 2 Glenn operation. The pulmonary blood flow would be 
mainly supplied from SVC but partially supplied from the inserted shunt. 
Blood within the systemic arteries has high potential energy because of its high 
pressure. In the standard Norwood circulation with mBTS, the high systemic pressure 
drives the pulmonary blood flow but this potential energy is partly dissipated through the 
shunt, which also acts as a resistive conduit to reduce pressure and flow to the level of the 
pulmonary circulation. In the ABG, however, a goal is to harvest some of this energy to 
augment pulmonary flow by using an ejector pump concept.  
An ejector pump, as illustrated by the conceptual drawing in Figure 1.7, converts 
high pressure energy into kinetic energy, such as through a nozzle. This high kinetic 
energy fluid is then used to do work on a secondary fluid that is at a lower pressure. This 
augments the flow rate of the secondary fluid. Ideally the energy of the high-pressure 
fluid is not wasted, but imparted to the secondary flow, as the kinetic energy diffuses 
within the secondary fluid converting back to pressure. In concept, the systemic 
circulation would serve as the high pressure source and would communicate with the 
secondary, lower pressure SVC flow through a systemic-to-caval shunt. The momentum 
of the jet would assist the caval flow to the pulmonary artery while it diffuses within the 





In the initial ABG concept [84], a ligaclip (surgical clip) was envisioned as being 
applied over the exterior of the shunt, near its junction to the SVC, narrowing the shunt 
and serving as the nozzle to convert high systemic pressure into kinetic energy. In 
concepts, the increased velocity after the nozzle is directed into the SVC where it adds 
momentum. This kinetic energy should be recovered as an increased pressure within the 
distal section of the SVC, which acts as the diffuser. In the ABG circulation, the ejector-
shunt is intended to increase pulmonary blood flow while maintaining or reducing the 
pressure gradient between the SVC and the pulmonary arteries. 
 
Figure 1.6 : Models illustration for mBTS (left), assisted bidirectional Glenn (middle), and BDG 
(right). AA, aortic arch including ascending aorta; DA, descending aorta ;CA, coronary arteries; 
PA, pulmonary arteries; SVC, superior vena-cava; BT, Blalock-Taussig shunt; ; BA, 
brachiocephalic artery ; RCCA, right common carotid artery. Qp, Qs, Qlb, and Qub denote 
pulmonary, systemic, lower body, and upper body flow rates. Cs, Cp, Cao denote systemic vein, 





Figure 1.7: Schematic of an ejector pump.
 
A goal of the ABG is to improve pulmonary blood flow and to do so without a 
large increase in SVC pressure. If successful, the ABG procedure would reduce the 
number of surgeries in the palliation strategy from 3 to 2. Later as the patient grows with 
concomitant reduction in PVR, the shunt could be occluded via a catheter to revert the 
ABG to a standard BDG. However, there remain questions about whether the concept can 
be successfully implemented and if so, how the nozzle should be designed, sized, and 
placed. Without the ejector effect, the ABG concept refers a resistive shunt pathway 
between the systemic circulation and the SVC. 
 
Research Aims  
This study tested the hypotheses that (1) it is possible to model the first and 
second stage palliation circulations using multi-scale in vitro circulation models, and to 
use these models to test novel surgical strategies, and if so, (2) test whether an ejector 
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pump advantage can be adopted in a superior cavo-pulmonary circulation, where the low-
energy pulmonary blood flow can be assisted by an additional source of high energy flow 
from the systemic circulation. 
 The specific aims of this study are: 
Aim 1: Construct multi-scale models for Stage 1 circulation and Stage 2 
circulation based on patient specific parameters obtained from clinical measurements. 
The function of these in vitro models will be verified and validated as an aid to surgical 
planning, predict clinical hemodynamics, and guide patient management. Discrepancies 
between the clinical measurements and experimental acquirement will be used to 
improve and modify the in vitro models.  
Aim 2: Use the validated Stage 1 and Stage 2 system to examine a conceptual 
novel surgery, called the assisted bidirectional Glenn procedure (ABG). Compare the 
performance of the ABG circulation to the performance of the Norwood circulation and 
the BDG circulation. Determine if an ejector pump effect can be developed within the 
proposed circulation. 
Aim 3: Assess the performance of the ABG circulation under parametric 
variations, e.g. varying shunts and nozzles having different shapes, sizes, and position 
and under adverse physical conditions, such as aortic coarctation and high pulmonary 
vascular resistance (PVR).  
Aim 4: Investigate respiration effects within the Stage 2 circulation as a means to 
better recapitulate time-based clinical measurements. Determine if there is an effect on 
the overall hemodynamics. 
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The following chapter will present the in vitro multi-scale models of Stage 1 and 
Stage 2 circulations. Numerical or clinical data will be used to validate the functionality 
of the models. In Chapter 3, a hybrid of validated Stage 1 and Stage 2 MCS will be 
presented to study the ABG circulation. In Chapter 4, parametric studies on SVC-to-aorta 
shunt will be conducted. In Chapter 5, aortic coarctation effects on the ABG will be 
investigated. In Chapter 6, the effects of respiration on Stage 2 circulation will be studied 
and discussed. In Chapter 7, a summary of main conclusions and limitations of this 





MULTI-SCALE IN VITRO MODELS  
This chapter details the in vitro Norwood circulation and Stage 2 Glenn 
circulation mock circulatory system models. Because the two models use similar 
components in their respective compositions, the elemental components are described 
together. 
Methods 
Mock Circulatory System 
The mock circulatory system (MCS) of the Norwood circulation is based on the 
multi-scale concept. A detailed multi-compartment LPN of the Norwood circulation was 
described by Esmaily-Moghadam et al. [84], and adopted as the reference to design this 
MCS. In order to design a practical MCS, obtaining sufficient dynamic accuracy with a 
minimal number of components, a reduced LPN of the Norwood circulation was derived 
from the full model by applying least-squares impedance matching with Thevenin 
equivalent circuit analysis. One example of the method to reduce the SVC branch is 
given in Appendix A.  
The reduced LPN model of the Norwood circulation is coupled with an 
appropriate three-dimensional (3D) model of the aorta, pulmonary artery, and 
anastomosis sites, as shown in the schematic of Figure 2.1 and the photograph of Figure 
2.3. It contains upper body (ub), lower body (lb), and pulmonary circulation branches. 
The pulmonary and upper body branches each included proximal (p) and distal (d) 
resistance elements (R), a compliance element (C), and the inertance of the vascular 
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tubing (L), known as a 4-element windkessel [85, 86]. One resistance element is used to 
control flow rate in the lower body. The appropriate hydraulic model was connected to its 
respective 3D model. In the Norwood circulation, a 3.5 mm diameter systemic to 
pulmonary shunt connected the innominate artery to the RPA.  
The circuit was operated between a mean aortic pressure and a mean atrial 
pressure. A ventricular assist device (VAD) was used to provide the pulsatile aortic 
pressure. A constant head tank was used to fix the atrial pressure. A saline-glycerin blood 
analog fluid was used (1060 3kg / m , 6 23.3 10 /m s  at 22 
oc ).  
The bidirectional Glenn (BDG) circulation MCS, shown in Figure 2.2, is very 
similar to the Norwood MCS except the test section. The BDG was modeled with a 
simple SVC to RPA anastomosis. 
 
Figure 2.1: The Norwood mock circulatory system lumped parameter network coupled with 3D 
anastomosis models for the Norwood circulation. C, compliance; ao, aorta; p, lung; up, upper 
body; R, resistance; lb, lower; ld, lung distal; llp, left lung proximal; rlp, right lung proximal; ubd, 




Figure 2.2: The BDG mock circulatory system lumped parameter network coupled with 3D 
anastomosis models for the BDG circulation. C, compliance; ao, aorta; p, lung; up, upper body; R, 
resistance; lb, lower; ld, lung distal; llp, left lung proximal; rlp, right lung proximal; ubd, upper 
body distal; ubp, upper body proximal; SVC, superior vena cava. 
 
Figure 2.3: Photograph of the MCS: 1, Atrium head tank; 2, Aorta proximal compliance element; 
3, SVC compliance element; 4, Berlin Heart VAD; 5, SVC resistance element; 6, flow meter; 7 
and 9, RPA and LPA resistance (valve) elements; 8, Test section; 10, pressure transducers. LPA 




Ventricular Assist Device and Aortic Pressures 
A ventricle assist device (VAD) (Excor®, 25 ml, Berlin Heart, Berlin, Germany) 
was used to simulate the single ventricle and to achieve a pulsatile ascending aortic 
pressure. The VAD includes two parts: a liquid filled side and an air filled side, divided 
by a flexible membrane. The schematic of the system used to operate the VAD is given in 
Figure 2.4. The VAD was operated pneumatically under computer control by alternating 
between high pressure applied during systole and venting to vacuum during diastole. 
Both the high and low pressures were regulated from source values using pressure 
regulators. The alternating pressure was manipulated using a three-way valve (Model: 
225B-111CAAA, MAC Valve, Dundee, MI, USA), which was controlled by an 0-5V DC 
analog signal provided by a data acquisition computer system (USB-6211 and Labview 8, 
National Instruments, Austin, Texas). The duration of the high pressure signal over one 
heartbeat determined the systolic time ratio. The cycling rate of the alternating pressure 
determined the heart rate. The high pressure and low pressure were tuned to obtain the 




Figure 2.4: Schematic of the VAD driving system. PC, computer; VAD, ventricle assisted device. 
 
Test Sections 
Test sections used in the Stage 1 validation were built using anatomical 
reconstructions of patients from clinical images reported in a formal study of mBTS [27]. 
In the Stage 2 verification and validation study, patient-specific anatomical details were 
acquired from real patient clinical imaging as recorded in the Leducq database. In 
creating the models, the tomographic model was reconstructed from computed 
tomography (CT) images. A 3D geometric virtual-space model was then built from 
magnetic resonance image (MR) data volumes by identifying the centerline path along 
the pulmonary artery from which perpendicular 2-D segmentations of the vessel lumen 
were created and then merged creating a solid (.stl file) model of the vessel [86]. The 
solid model was prepared for use as an experiment test section, including adding 
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extensions for tube fittings. The modifications of the models were done using commercial 
modeling software (3-Matic®, Materialise, Leuven, Belgium).  
The test models used in this study were all created either by high resolution 
stereolithographic printing either from Watershed 11122® material to a layer resolution 
of better than 0.05 mm, or by impact jet printing using Verowhite® material 
(Verowhite®, Stratasys, Minnesota, USA) to a resolution of 0.030 mm - 0.016 mm [67]. 
Variations of this manufacturing technique have been reported previously [87-90]. 
 
Resistance Elements 
Flow resistance elements were used to fix the resistance parameters throughout 
the circuit. Flow resistance is defined as /nR p Q  , where p  and Q are the pressure drop 
and flow rate across the element, respectively [55]. The value of n varies from 1 (laminar 
flow) and ½ (fully turbulent flow). Two main methods were used to achieve specific 
resistance values, namely, ball valves and laminar resistance elements. Ball valves are 
convenient for changing the resistance value in situ, but this resistance value is not linear 
with flow rate. Given the low flow rates and the small changes in flow rate used in these 
circulations and the fact that the resistance was set individually for each test case, 
nonlinearity was not an issue. A laminar resistance element was created by packing a 
tube with bundles of capillary tubes. These laminar elements provided a resistance that 
was linear with flow rate and used where resistance values were small. The residual 
tubing and connectors also added a resistance to flow. The stated elemental resistance 
value R was determined in situ by measuring the pressure drop and mean flow rate 
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between sections or nodes of each branch of the system under a steady flow condition. 
The method used to develop laminar resistance element and resistance element 
calibration is described in Appendix B, and consisted of measuring the pressure drop 
across an element at a known steady flow rate consistent with the intended position of the 
element within the MCS. 
 
Compliance Elements 
Compliance is used to simulate the elastic volume change of a vessel during 
pressure variation. The compliance value was determined by /C p   , where   is 
the change of volume according to pressure change p . 
The upper body and aorta compliances were developed by using air chambers 
(also called “windkessels”), each consisting of a vertical cylinder made of clear 
polyvinylchloride (PVC), capped at one end and partially filled with water and air, and 
sealed at the top with a moveable plumber test plug (Oatey Corp, Cleveland, OH). 
Compliance is obtained by compression of the trapped air as more water enters the 
chamber from the MCS. The plug is set to trap a desired volume of air, in order to attain 
the desired compliance value. One of the air chambers is shown in Figure 2.5. Another 
type of compliance element used elastic tubes to simulate respiratory dynamics in the 
MCS, and is discussed in Chapter 6. The method used for compliance element calibration 
is described in Appendix C, and consisted of measuring volume change for an applied 
pressure change. The elements were found to be essentially linear over the pressure 






Inertance refers to the pressure gradient required to accelerate a mass of fluid. 
Fluid inertance mimics the electrical property of an inductor. The inertance in a fluid 
system creates a pressure drop while a flow accelerates. The relationship can be described 
as: ( / )p L dQ dt  , where L is the inertance value. The formula for L is: /L l A , in 
which  is the fluid density , l  and is the conduit length and A  is cross sectional area. 
Inertance is real in a physiological system but tends to be small in infants. In order 
to keep the inertance effect realistic within an in vitro system, inertance is controlled by 
minimizing the tube length between system elements while avoiding smaller diameter 
tubes, so as to provide for a compact bench system. Excess inertance manifests itself as 
 





accentuating the pressure amplitude and increased time-lag in the time-based signals. 
Efforts were taken to minimize extraneous inertance in the MCS. 
 
Measurement Systems 
Flow rate was measured at various points throughout the MCS, including the 
lower body branch, SVC, LPA and RPA. Each flow rate was measured by an in-line 
square wave electromagnetic flow probe with control box (P600 series probe, FM501 
Control unit, Carolina Medical Electronics, East Bend, NC). The photographs of the flow 
meter and flow probe are shown in Figure 2.6 (Upper). Pressures are measured either by 
catheter or wall tap and by blood pressure transducers (DTX-Plus; BD Medical, Austin, 
TX) driven by bridge amplifiers (Model 2300, Micromeasurement Group, Raleigh, NC) 
as shown in Figure 2.6 (Lower). All transducer signals were operated and recorded using 




Figure 2.6: FM501 Electromagnetic flow meter (Upper left) and EP640 flow probe (Upper right); 
blood pressure transducers (lower left) and bridge amplifiers (lower right). 
 
LPN Parameters 
The Stage 1 Norwood circulation MCS used has been validated in previous 
studies [48, 67]. A verification of the MCS flow and pressure results against those 
predicted by a numerical model was presented for the Stage 1 MCS verification study. 
The multi-scale numerical model is described by Esmaily-Moghadam [84] and used a 
higher order LPN than the experimental model but with identical 3D models. 
The elemental LPN component values of Stage 1 were obtained from a prior 
study that incorporated clinical catheterization and angiographic data from 28 Norwood 
patients [26]. These values were the same used in the numerical model [84]. For the 
experimental model, the number of elements in the LPN was reduced using Thevenin 
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equivalency, as previously described. Values with uncertainty (details in Appendix D) for 
the impedance elements used in the MCS are given in Table 2.1 for the two cases of 
indexed PVR tested: 2.3 and 7.0 WU-
2m  [1.0 WU = 1 mm Hg/Liter per minute (LPM)]. 
This range addresses patient growth from the neonatal (high PVR) to the larger infant 
size (low PVR) more common at the time of the Glenn surgery.  
 
The LPN elemental values used for the Stage 2 circulation were calculated 
directly from clinical measurements of catheter pressures and MR flow rates. The 
specific parametric values with uncertainty used are listed in Table 2.2. One patient case 
occurs at surgical time point 5, which corresponds to just before the Stage 3 Fontan 
surgery. In order to maintain confidentiality, the patient is designated here as UM2_TP5 
(UM, University of Michigan), where the acronym refers to the patient’s clinical center 
and the numerical value identifies the patient’s record. 
 
Table 2.1: Stage 1 study elemental values for experimental lumped parameter network model 
Parameters Experimental values 




























R, Resistance [mmHg.s/ml]; C, Compliance [ml/mm Hg]. Subscripts: lb, Lower body; upd, 
Upper body distal; upp, Upper body proximal; rlp, Right lung proximal; llp, Left lung proximal; ld, Lung 





Time-based experimental signals used in the comparisons were ensemble-
averaged over 20 consecutive heartbeats. Pressure and flow rate signals from the 
numerical and/or experimental models were compared point-to-point at corresponding 
times using linear regression (y = x) from which a coefficient of determination (R2 value) 
was calculated (details in Appendix E). An unpaired Student’s t-test (details in Appendix 
F) was used to compare the mean values, such as a numerical or clinical mean value to an 
experimentally measured mean value. A p-value (details in Appendix F) of 0.05 or less 
was considered to indicate that a statistically significant difference existed between the 
two tested mean values. A point-by-point root-mean-square error (rms error) was 
calculated between two time-based signals to compare the experimental measurements 
with the corresponding numerical or clinical signals. The rms error was normalized by 
Table 2.2: LP elemental values for Stage 2 validation study 
Parameters Unit UM2_TP5 
Pao mmHg 73±0.5 
Pat mmHg 6±0.1 
Rlb mmHg.s/ml 5.01±0.12 
Rubd mmHg.s/ml 3.73±0.09 
Rubp mmHg.s/ml 0.12±0.01 
Cup ml/mmHg 0.45±0.02 
Rrlp mmHg.s/ml 0.13±0.01 
Rrld mmHg.s/ml 0.37±0.02 
Crl ml/mmHg NA 
Rllp mmHg.s/ml 0.67±0.03 
Rlld mmHg.s/ml 0.22±0.01 
Cll ml/mmHg NA 
Cao ml/mmHg 0.25±0.02 
HB times/min 84 
 
C, Compliance; LB, Lower body; LL, Left lung; LLD, Left lung distal; LLP, Left Lung Proximal; 
LP, Lumped parameter; LPN, Lumped parameter network; R, Resistance; RL, Right lung; RLD，Right 
lung distal; RLP, Right lung proximal; RR, Respiration rate; UP, Upper body; UPD, Upper body distal; 
UPP, Upper body proximal. TP4, Time point 4, just post Glenn surgery; TP5, Time point 5, pre Fontan 
surgery. Set value± uncertainty (95% confidence level) 
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the mean value, and is reported as   = rms error/mean (details in Appendix G). A value 
of 10% or less than was considered to indicate a good fit of the experimental model to the 
data (clinical data or numerical data in this study). 
 
Results 
Verification Results for Stage 1 MCS 
The time-based signal comparisons between numerical and experimental Stage 1 
Norwood with mBTS models are shown in Fig. 2.7 for both values of PVR. The signals 
are plotted over a single heartbeat and have been ensemble averaged over 20 continuous 
heart beats. Both experimental and numerical predictions [84] of pressures within the 
pulmonary arteries are higher at the higher PVR, as expected, and the pulsatility of the 
flow rate corresponding to the heart beat cycle is seen. LPA and RPA flows and pressures 
are well-reproduced between the models (0.62 < 2R  < 0.74). The numerical model 
predictions of flows and pressures show higher frequency content than the experimental 
model measurements but the mean values compared very well and showed no statistically 
significant differences (p > 0.05) between the two models, verifying the capability of the 
experimental setup. The numerical signals for RPA and LPA pressures show more 
pulsatility compared with the experimental model measurements, which was likely a 
pulmonary compliance mismatch between the two models. The calculated   was < 5% 





Figure 2.7: Time-based experimental (solid) and numerical (dashed) flow rate and pressure signal 
comparisons for the mBTS circulation under low and high values of pulmonary vascular 
resistance (PVR). Subscript: 1, low PVR (2.3 WU-
2m ); 2, high PVR (7.0 WU- 2m ).  
 
Verification and Validation Results for Stage 2 MCS 
In order to test and verify the Stage 2 MCS, a validation test against clinical data 
was performed. The time-based experimental and clinical ascending aorta pressures are 
shown in Figure 2.8, respectively for the patient UM2, using TP 5. The ascending aorta 
pressure was used as an input waveform to drive the MCS; the comparison verifies that 




The experimentally measured flow rates, and corresponding clinical data from the 
Leducq database, are shown in Figures 2.9 - 2.11. The measured SVC flow rate signal 
matched well with the clinical flow rate with satisfactory amplitude and phase matching 
( 2R  =0.84, p > 0.05). The calculated relative root mean square error  was < 5%, 
demonstrating the model followed and predicted the clinical data.  
The experimental RPA flow rate signal matched well with the clinical 
measurement with satisfactory amplitude and phase matching ( 2R  = 0.78, p > 0.05). The 
calculated  < 6% and considered acceptable.  
The tested LPA flow rate matched well with the clinical measurement with 
satisfactory amplitude and phase matching ( 2R  = 0.92, p > 0.05). The calculated   < 3%, 
provided a good prediction of the clinical data.  
In summary, the agreement between experimental and clinical pressure and flow 
rates were reasonable with satisfactory amplitude and phase matching (0.6 < 2R < 0.97, p > 
0.05). The close agreement validates the ability of the experimental model to recapitulate 
certain clinical measurements of an individual patient. Such a level of validation has 






Figure 2.8: Comparison between clinical and experimental results of ascending aorta pressure 




Figure 2.9: Comparison between clinical and experimental SVC flow rate for UM2, time point 5. 
CLI, clinical; SVC, Super vena cava. 
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Figure 2.10: Comparison between clinical and experimental RPA flow rate for UM2, time point 5. 
CLI, clinical; RPA, right pulmonary artery. 
             
Figure 2.11: Comparison between clinical and experimental LPA flow rate for UM2, time point 5. 





In this chapter, two in vitro multi scale mock circulatory systems capable of 
simulating either the Stage 1 Norwood with mBTS or the Stage 2 bidirectional Glenn 
circulation were verified and validated by comparing experimental measurements with 
numerical or clinical data. The in vitro MCS demonstrated the following capabilities: (1) 
The MCS can capture both the global and local response of the system, (2) the system 
can be tuned to match patient specific LPN parameters and use accurate 3D models of the 
anastomosis.  
The VAD used in the open-loop MCS was not intended to be a consistent model 
of ventricle dynamics, nor would that be appropriate, but rather it provided a sufficiently 
realistic source of flow and pulsatility for the experimental system. As the VAD does not 
match the preload and afterload sensitivity of a natural heart, the VAD was adjusted in 
the MCS to maintain a predetermined mean aortic pressure, with HR and atrial pressures 
fixed. This approach mimics long-term baroregulation of the heart. In order to simplify 
the experimental setup, the coronary circulation is not modeled.  
Although we have developed and used compliant 3D test sections in the MCS in 
the past [82, 55], the models used here were rigid. However, by using a lumped proximal 
aortic compliance we do not anticipate significant differences in the hemodynamic data 
presented. Vukicevic et al. [74] showed that in practice, a lumped compliance element 
proximal to a rigid three dimensional test section in a multiscale MCS can accommodate 
the noncompliant test section to produce clinically realistic pressure waveforms. 
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The data required for tuning of the circuit sometimes must rely on generic 
information taken from literature, because clinical measurements were limited by the 
Leducq protocol. Gravitational variation was not part of this experimental program. The 
test design assumed the patient to be in the supine position under resting conditions, as 
small children typically are in cardiological testing. The MCS can be tuned for exercise 








THE ASSISTED BIDIRECTIONAL GLENN STUDY 
 
In this section, a mock circulatory system of the conceptual ABG circulation is 
presented and based on the previously described Stage 1 and Stage 2 mock circulatory 
systems. The performance of the conceptual ABG circulation was tested and assessed by 
comparing directly with the performance of the Stage 1 Norwood circulation and the 
Stage 2 bidirectional Glenn (BDG) circulation for hypothetical patients. The 
experimental results are also compared to those of a multi-scale numerical model [84] 
and previously published [83]. 
Methods  
Mock Circulatory System 
The physical system of the ABG circulation is built from the Stage 1 and Stage 2 
MCS discussed in Chapter 2. The schematic of the ABG circulation is depicted in Figure 
3.1. In the ABG, a 2.5 mm diameter shunt with a nozzle was connected between the 
innominate artery and the SVC just above the SVC-PA junction, while the remaining 
circulation resembled the BDG. The performance of the ABG is tested using the LPN 
parameters listed in Table 2.1. To model the ejector effect, a surgical ligaclip was placed 
over the shunt as proposed by Esmaily-Mghadem [84]. Tests were run using two patients 





Figure 3.1: The ABG Mock circulatory system lumped parameter network coupled with the ABG 
three dimensional anastomosis. Cao, aorta compliance; Cl, lung compliance; Cup, upper body 




Experimental results were compared directly to the multi-scale numerical results 
reported by Esmaily-Moghadam [84]. In the experimental model, the nozzle diameter d 
to shunt diameter D (or β= d/D) was modeled exactly as in the numerical study. Because 
the nozzle was created by a clip, a hydraulic diameter for the nozzle was used. The 
resulting β = 0.57. The measured input conditions of time-based ascending aortic 
pressure are given in Figure 3.2 with mean values in Table 3.1 and compared directly to 
the numerically applied waveforms. The time-based agreement between experimental and 
numerical was quite good (0.64 < 2R  < 0.86, p > 0.05) and mean aortic pressures were 
well within 1.0 mmHg difference. The calculated rms error ranged from 3.0% to 7.0%. 
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The good matching between the time-based aortic pressures indicates that the input 
waveform used were the same in both cases. 
 
Figure 3.2: Time-based ascending aortic pressures applied in the experimental and numerical 
studies  
2R  , coefficient of determination;  , rms error. 
 
Mean flow comparisons, given in Figure 3.3 with mean values in Table 3.1 were 
nearly identical between the numerical and experimental results (p > 0.05). Pulmonary 
blood flow is highest for the mBTS circulation, while the ABG circulation provides a 30% 
to 38% improvement in pulmonary blood flow over the BDG circulation. SVC flows are 
comparable between circulations at normal PVR (p > 0.05). SVC flow increases with 
PVR in the mBTS circulation, where SVC competes with the shunt, but decreases for the 
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ABG and BDG circulations. Pulmonary pressures are highest for the mBTS circulation 
and lowest with the BDG circulation.  
 
 
Table 3.1: Mean pressure (P), flow rate (Q), and oxygen delivery (OD) comparisons between 
















 Unit       
Pao 
 
CFD mmHg 52.1 54.6 55.2 53.7 51.8 54.9 
EXP mmHg 52.0±0.2 54.5±0.2 55.1±0.2 54.1±0.4 51.6±0.4 54.2±0.4 
Psvc 
CFD mmHg 2.51 6.01 7.91 2.41 11.13 14.94 
EXP mmHg 2.4±0.1 6.1±0.1 8.1±0.1 2.5±0.1 11.0±0.1 14.7±0.1 
Plpa 
CFD mmHg 9.55 4.89 6.11 18.28 10.20 13.51 
EXP mmHg 10.6±0.1 5.0±0.1 6.7±0.1 18.5±0.1 9.9±0.1 13.8±0.1 
Prpa 
CFD mmHg 7.85 4.86 6.11 20.12 10.18 13.51 
EXP mmHg 9.0±0.1 4.8±0.1 6.8±0.1 19.2±0.1 10.1±0.1 14.1±0.1 
Qsvc 
CFD L/min 0.48 0.50 0.47 0.50 0.42 0.40 
EXP L/min 0.47±0.01 0.48±0.01 0.46±0.01 0.51±0.01 0.42±0.01 0.40±0.01 
Qlpa 
CFD L/min 0.40 0.25 0.32 0.38 0.21 0.29 
EXP L/min 0.41±0.01 0.25±0.01 0.32±0.01 0.38±0.01 0.21±0.01 0.29±0.01 
Qrpa 
CFD L/min 0.52 0.25 0.32 0.42 0.21 0.28 
EXP L/min 0.52±0.01 0.25±0.01 0.32±0.01 0.42±0.01 0.21±0.01 0.29±0.01 
Qlb 
CFD L/min 0.61 0.67 0.66 0.63 0.64 0.66 
EXP L/min 0.61±0.01 0.67±0.01 0.66±0.01 0.63±0.01 0.63±0.01 0.66±0.01 
Qshunt 
CFD L/min NA NA 0.17±0.03 NA NA 0.17±0.03 
EXP L/min NA NA 0.18±0.03 NA NA 0.18±0.03 
Qs 
CFD L/min 1.09 1.17 1.13 1.13 1.06 1.06 
EXP L/min 1.08±0.02 1.15±0.02 1.12±0.02 1.14±0.02 1.05±0.02 1.06±0.02 
Qp/Qs 
CFD - 0.85 0.43 0.58 0.71 0.40 0.54 
EXP - 0.86±0.01 0.43±0.01 0.57±0.01 0.70±0.01 0.40±0.01 0.55±0.01 
CO 
CFD L/min 2.01 1.17 1.31 1.93 1.06 1.23 
EXP L/min 2.01±0.01 1.17±0.01 1.30±0.01 1.94±0.01 1.05±0.01 1.24±0.01 
OD 
r = 0.5 
CFD mLO2/s 2.96 3.25 3.38 2.92 2.79 3.07 
EXP mLO2/s 2.95±0.27 3.21±0.27 3.34±0.27 2.93±0.27 2.76±0.27 3.09±0.27 
OD 
r = 0.4 
CFD mLO2/s 2.96 3.48 3.54 2.92 3.01 3.24 
EXP mLO2/s 2.95±0.27 3.40±0.27 3.49±0.27 2.93±0.27 2.98±0.27 3.25±0.27 
OD 
r =0.7 
CFD mLO2/s 2.96 2.87 3.09 2.92 2.36 2.76 
EXP mLO2/s 2.95±0.27 2.79±0.27 3.03±0.27 2.93±0.27 2.32±0.27 2.77±0.27 
L: normal PVR; H: high PVR; ao, aorta; svc, superior vena cava; lpa, left pulmonary artery; rpa, right 





Figure 3.3: Numerical and experimental value comparisons of mean flow rate and pressure for the 
three circulations. CFD, numerical; EXP, experimental; LPA, left pulmonary artery; RPA, right 
pulmonary artery; SVC, super vena cava; PVR, pulmonary vascular resistance 
Oxygen delivery (OD) was calculated using the method detailed in Appendix H 
using measurements of flow rates to the various circulation branches. As indicated in 
Figure 3.4 and Table 3.1, the ABG circulation provided the highest systemic OD of the 
three circulations regardless of PVR (p > 0.05). Differences between experimental and 
numerically predicted mean values for each circulation showed no significant difference 
(p > 0.05). When the oxygen consumption ratio was varied from r = 0.4 to r = 0.7 (Table 
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3.1), the ABG circulation also provided the highest OD. Notably, as the value of r was 
increased in the ABG. 
Time-based signal comparisons between numerical and experimental mBTS, 
BDG and ABG models are given in Figure 2.7, Figure 3.5 and Figure 3.6, respectively. 
Time-based LPA and RPA flows and pressures are well reproduced between the models 
(0.74 < 2R  < 0.91). Mean values were nearly identical (p > 0.05). The calculated root 
mean square error   ranged from 1.0% to 5.0% for both flow rate predictions and 
pressure predictions. In the ABG model, the numerical prediction of SVC flow shows 
somewhat more pulsatility during systole than the experiment ( 2R  = 0.61); however, the 
maximum, minimum and mean values compare very well and the time-based SVC 
pressures are nearly identical between the models.  
 
Figure 3.4: Comparison of experimental estimations of systemic oxygen delivery among BT-




Figure 3.5: Time-based experimental (solid) and numerical (dashed) flow rate and pressure 





This chapter presents an in vitro multi-scale model of the Norwood with mBTS 
and Glenn (BDG) circulations and used it to explore a novel approach for a first stage 
palliation of univentricular physiology called the ABG circulation. 
The ABG circulation augmented pulmonary blood flow in a superior 
cavopulmonary connection using a shunt ending in a nozzle so as to supply high-energy 
flow from the systemic circulation. Based on ejector pump concepts, the approach 
improved systemic OD and achieved balanced systemic and mixed venous saturation 
 
Figure 3.6: Time-based experimental (solid) and numerical (dashed) flow rate and pressure signals 




while maintaining clinically acceptable SVC pressures [83]. Also, increasing pulmonary 
arterial blood flow should off er several benefits including higher pulmonary arterial 
pressure and improved saturation over the Glenn [91]. McElhinney et al. [92] suggest that 
these would allow for improved exercise tolerance and reduce baseline cyanosis. The 
ABG adds a component of pulsatility to the pulmonary blood flow, which could 
potentially improve pulmonary vascular development and exercise tolerance [92, 93].  
 
Ejector Pump Effect Analysis 
The hypothesis that an ejector pump advantage can be adopted in a superior cavo-
pulmonary circulation, where the low-energy pulmonary blood flow can be assisted by an 
additional source of high energy flow from the systemic circulation was investigated. But 
there is no prior approach to calculate the magnitude of ejector pump effect. In Zhou et 
al.[83], the eff ect of the ejector-shunt was quantified by comparing the pressure 
difference between the SVC and pulmonary artery (PA) relative to the total pulmonary 
blood flow. From Table 3.1, while this pressure gradient ( SVC PAP P ) remains about the 
same between the BDG and the ABG circulations, the corresponding pulmonary blood 
flow ( LPA RPAQ Q  ) is increased in the ABG over the BDG. So the pulmonary blood flow 
is increased 30 – 38% for the two conditions studied for the same pressure gradient. In 
effect, the ejector-shunt effect reduces the local flow resistance at the SVC-PA junction.  
This method gave a general idea on how to access the ABG improvement over the 
BDG in neonates. But in essence, the BDG and ABG have different physiological 
structures. The increased pulmonary blood flow in the ABG compared with the BDG 
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arises from the shunt. But does the nozzle present an “ejector offset” as proposed or is the 
ABG performance a result of the resistant shunt only or something in between? 
An idea naturally came out was to compare the ABG performance with an “ABG” 
which had no ejector effect. This could be achieved by removing the nozzle far away 
from the shunt-SVC junction, close to the aorta side of the shunt. In order to examine if 
the nozzle produced the ejector effect, a test was done to compare the hemodynamics 
with three different nozzle placements as shown in Figure 3.7: one 2.5 mm diameter 
shunt was coupled with a tapered nozzle having a β of 0.60 at the positions of (A) 0 mm; 
(B) 3 mm; and (C) 6 mm away from the SVC-shunt junction. 
 
Figure 3.7: Schematic of the shunts tested to examine the ejector pump effect. L is the distance 
from the nozzle to the Shunt-SVC junction. 
In theory, the resistance of the three shunts should be equivalent. If the ejector 
effect exists, the C type shunt should produce the weakest ejector pump effect, since the 
long distance would allow the flow to recover the pressure and attenuate any ejector 
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effect. The tested results, including the pressure and flow signals of the SVC, LPA, and 
RPA branches are given in Figure 3.8. As the nozzle was moved from L = 0mm to 6mm, 
the SVC pressure increased about 0.6 mmHg and the pulmonary pressure declined about 
0.3 mmHg. The SVC flow decreased 0.01LPM as the nozzle was moved away from the 
SVC. To clearly demonstrate the nozzle effect, two parameters were calculated. The first 
one was the SVC and pulmonary artery (PA) pressure difference. The second was the 
SVC and PA pressure difference relative to the PA flow rate, which was defined previous 
as the ejector resistance [83]. The final calculated results were given in Figure 3.9. Shunt 
A demonstrated the lowest SVC and pulmonary artery pressure difference and the least 
ejector resistance between the three shunts for either value of PVR. This result 
demonstrates the existence of an ejector effect. Also from Figure 3.9, the ejector effect 
weakened as PVR increased, as expected. Future work may explore more advanced 




Figure 3.8: Tested pressures and flows between three different shunts. A: 2.5mm shunt; B, 1.5mm 
shunt; C, 2.5mm shunt attached a tapered nozzle with a β of 0.6; LPA, left pulmonary artery; 




Figure 3.9: Tested SVC to pulmonary artery pressure difference and ejector resistance between 




In summary, the hypothesis that an ejector pump advantage can be adopted in a 
superior cavo-pulmonary circulation, where the low-energy pulmonary blood flow can be 
assisted by an additional source of high energy flow from the systemic circulation was 
validated. The ABG could be used as a Stage 1 palliation option for single ventricle heart 
disease patients. It could provide more stable pulmonary blood flow source and relieve 







THE ABG NOZZLE PARAMETRIC STUDY 
 
In the previous study of the ABG circulation, the shunt and geometries were fixed 
to compare to a numerical study. In this chapter, parametric studies are presented of the 
shunt and nozzle used in the ABG connecting the SVC and systemic circulation. Results 






The shunt orientation and nozzle characteristics are investigated. Investigated 
parameters include: nozzle hydraulic diameter to shunt hydraulic diameter ratio β, nozzle 
angle o , nozzle position L relative to the SVC-shunt junction, and nozzle shape. The 
studies are made using PVR values of 2.3 2WU m  and 7 2WU m  within the ABG 
circulation MCS model. 
 
Nozzle Designs 
Four nozzle designs were used and these are shown in Figure 4.1. These include: 
a concentric nozzle, a tapered shunt, a protruding nozzle extending into the SVC, and an 
external banded shunt (surgical ligaclip design of [84]). Location of the nozzle within the 
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shunt is designated as L, with L= 0 placing the nozzle at the shunt-SVC junction (Figure 
4.1). Shunt angle is measured relative to the SVC. Nozzle diameter d is varied relative the 
shunt diameter D, where β =d/D as before. Shunt diameter is fixed at D = 2.5mm for all 
tests. 
The concentric nozzle (Fig 4.1) allows for variations of β (nozzle diameter to 
shunt diameter) in a controlled manner over a range of 0.24 < β < 0.84. The nozzle was 
situated within the shunt at the SVC-shunt junction (L = 0mm) and shunt angle θ was 
held constant at 40 degrees (Figure 4.1) in these tests.  
The effect of the SVC-shunt angle (θ) on the ABG performance was also 
investigated. Five angle configurations (20º, 30º, 40º, 50º, 60º) were tested in this study 
with β set to 0.6 and L set to 0 mm (Figure 4.1, subfigure D, details of the parameters are 
shown in subfigure E) using the concentric nozzle. In order to study the nozzle position 
effects, four different positions were tested: L = -1.5mm, 0mm, 1.5mm and 3.0mm. A 
positive value means that the nozzle was located within the SVC branch; a negative value 
represents that the nozzle was located within the shunt towards the aorta, relative to L = 0, 
the SVC-shunt intersection.  
Nozzle shape may have an effect on the ABG performance, so a convergent 
tapered nozzle, shown in Figure 4.1 (subfigure C), was tested and the results were 
compared to the previously introduced concentric divergent nozzle sharing the same L, β 
and θ.  
One idea is to move the high energy blood flow from systemic circulation closer 
to the pulmonary artery. To study this, a nozzle that protrudes into the SVC (Figure 4.1, 
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subfigure D) was used. Nozzle protrusion into the SVC could produce a sizable blockage 
effect, which may unfavorably increase SVC pressure upstream of where the nozzle 
protruding into the SVC. So a curved nozzle was designed to reduce the blockage area. 
The STL model and photograph of the inside view of the nozzle are shown in Figure 4.1 
(subfigure A).  
Overall, the tests used 16 different nozzle designs of nozzle shape, nozzle-to-
shunt hydraulic diameter ratio β, position L and angle θ in the ABG circulation. The 
parameters of the 16 designs are presented in Table 4.1. The design with case number 4 
(concentric nozzle, β = 0.60, L = 0, θ = 040 ) was compared in all the 4 study categories.  
 
Figure 4.1: The Assisted Bidirectional Glenn shunt location. Ligaclip nozzle/shunt geometry is 






Results of the nozzle parametric tests are given in Figure 4.2 to Figure 4.6 and 
Table 4.2 and Table 4.3. The parametric effects are discussed below. 
 
Diameter effects 
In studies using the concentric nozzle, Figure 4.2 shows the resulting time based 
flow and pressure traces as functions of diameter ratio β. Table 4.2, Table 4.3 and Figure 
4.3 summarize the mean results. The standard error for each measurement was also 
included in Table 4.2 and Table 4.3. The experimental results for the original ligaclip 
design geometry (β = 0.57) are also provided for comparison. As shown in Figure 4.2, all 
Table 4.1: Design parameters matrix of the nozzle tested. 





1 Concentric 0.60 2.5 0.24 40 0 NO 
2 Concentric 0.90 2.5 0.36 40 0 NO 
3 Concentric 1.20 2.5 0.48 40 0 NO 
4 Concentric 1.50 2.5 0.60 40 0 NO 
5 Concentric 1.80 2.5 0.72 40 0 NO 
6 Concentric 2.10 2.5 0.84 40 0 NO 
 
Angle (θ) 
7 Concentric 1.50 2.5 0.60 20 0 NO 
8 Concentric 1.50 2.5 0.60 30 0 NO 
4 Concentric 1.50 2.5 0.60 40 0 NO 
9 Concentric 1.50 2.5 0.60 50 0 NO 





11 Tapered 1.50 2.5 0.60 40 0 NO 
4 Concentric 1.50 2.5 0.60 40 0 NO 
12 Protruded 1.50 2.5 0.60 40 0 YES 




14 Concentric 1.50 2.5 0.60 40 -0.15 NO 
4 Concentric 1.50 2.5 0.60 40 0 NO 
15 Concentric 1.50 2.5 0.60 40 0.15 NO 
16 Concentric 1.50 2.5 0.60 40 0.30 NO 
d, nozzle minimum diameter; D, shunt diameter; L, Distance between nozzle and SVC-Shunt junction; β, 
nozzle diameter to shunt diameter ratio; θ, shunt angle. 
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pressures and flows became more pulsatile with the increasing β values, as more arterial 
pulsatility was communicated through the shunt. Mean RPA and LPA pressures and 
flows increased, as expected, as β increased. The LPA pressure increased from 5.0 
mmHg to 11.0 mmHg as PVR increased from 2.3 WU- 2m  to 7.0 WU- 2m . The similar 
trend was seen in the RPA and SVC pressures. The value of Qp / Qs was sensitive to β 
but not to PVR; it varied from 0.44 to 0.74 as β increased from 0.24 to 0.84. For PVR 
value of 2.3 WU- 2m , as β increased from 0.24 to 0.84, the shunt flow increased from 
0.04 LPM to 0.36 LPM, and the cardiac output increased from 1.16 LPM to 1.43 LPM. 
This was due to a larger β, which yielded a smaller flow resistance. For β = 0.72 and 
above, SVC pressure rose above 18.0 mmHg, and SVC flow dropped noticeably as the 
increasing shunt flow competed with increasing SVC pressure. Geometries using a β 
between 0.48 and 0.60 showed high systemic oxygen delivery (OD) (Fig 4.3) with 
calculated values above 3.00 
2
ml /O s . Inspection of OD and measured pressure and 
pulmonary flow suggests that a good value for β falls between 0.48 and 0.60. 
 
Angle effects 
The concentric nozzle was used as SVC-shunt angle was varied between
20 60o o  . For these tests, the β value was kept constant at 0.60 and L = 0. Details of 
the parameters are listed in Table 4.1 (case 7 to 11). The input aortic pressure kept 
constant at 50.5 mmHg for all the cases. The mean values of the measured and calculated 
parameters are given in Figure 4.4 and Table 4.2 to 4.3.  
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The SVC pressure remained constant between 8.2mmHg to 8.7mmHg for PVR at 
2.3WU- 2m  and 15.2mmHg to 15.6mmHg for PVR at 7.0 WU- 2m as angle varied. This 
variation is well within clinical significance, indicating that SVC pressure was not very 
sensitive to shunt angle. The tendency was repeated in the LPA and RPA pressures. 
The pulmonary artery flow rate decreased about 0.01-0.02 LPM as pulmonary 
vascular resistance (PVR) increased from 2.3 to 7.0 WU- 2m  for all the tested angles. For 
all angles, the lower body flow rate remained constant between 0.64 ~ 0.65 LPM with 
PVR. 
The LPA and RPA flow rates reached a maximum (0.33 LPM for 2.3 WU- 2m  
and 0.32 LPM for 7.0 WU- 2m  ) at an angle of 30o  and then decreased as angle increased 
for either PVR values. But the difference among different angles was small (maximum 
difference 0.02 LPM, 6% absolute).  
The SVC flow rate reached a maximum of 0.44 LPM at an angle of 30o  for 2.3 
WU- 2m case and a maximum of 0.42 LPM at an angle of 40o  for 7.0 WU- 2m case and 
then decreased as angle increased. But the difference among different angles was small 
(maximum difference 0.04LPM, 10% absolute). The cardiac output (CO) showed a 
similar trend and reached a maximum at an angle of 30o . 
The shunt flow reached a maximum at the angle of 30o  and then deceased as the 
angle θ decreased for either PVR values. It should be noted that the shunt flow was not 
measured directly. It was calculated with mass continuity and the uncertainty was 0.03 
LPM (details in Appendix D). Accordingly, differences between the shunt flows between 
angles were not statistically significant. 
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The oxygen delivery (OD) attained its highest value at an angle of 30o  and o40  
for either value of PVR. The range of OD varied 9.5% (3.35 
2mlO / ml  compared with 
3.06 
2mlO / ml ) between the best and the worst cases. 
In summary, the influence of angle θ on the ABG performance was not significant. 
Shunt angle of 30o  to 40
o showed a slight improvement on pulmonary blood flow and 
oxygen delivery over other angles. A recommended angle was between 30o  and 40o . 
 
Shape Effects 
Four different shapes, including the initial proposed ligaclip nozzle, a concentric 
internal nozzle, a tapered nozzle and a protruding tapered nozzle, were tested to examine 
the nozzle shape effects on the ABG circulation. For these tests, the β was kept constant 
at 0.6, θ was set at o40  and the location L was set at 0 mm. 
The mean values of the measured and calculated parameters are given in Figure 
4.5 and Table 4.2 to 4.3. For these tests, the aortic pressure was kept constant at 50.5 
mmHg for either value of PVR and each shape design. 
The SVC pressure remained constant around 8.2 mmHg for PVR at 2.3 WU- 2m  
and around 15.6 mmHg for PVR at 7.0 WU- 2m with variation in nozzle shape, except for 
ligaclip due to its smaller β value (0.57 compared with 0.60). This suggested that the 
shapes tested did not influence the SVC pressure. The similar trend was shown in the 
LPA and RPA pressures. 
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The pulmonary artery flow decreased by about 0.01~0.02 LPM as pulmonary 
vascular resistance (PVR) increased for all the tested shapes. For either shape, the lower 
body flow rate remained nearly constant between 0.64 ~ 0.65 LPM for either value of 
PVR.  
The LPA flow rate remained constant at 0.32 LPM with nozzle shape variation, 
suggesting the LPA flow rate was not sensitive to the nozzle shapes tested. As the LPN 
values were set the same in the two pulmonary branches, the same trend was seen in the 
RPA. 
The SVC flow rate stayed constant at 0.42 LPM for 2.3 WU- 2m and 0.39 LPM for 
7.0 WU- 2m  for the different nozzle shapes, showing the SVC flow was slightly sensitive 
to PVR but was not sensitive to the nozzle shapes tested.  
The differences between the shunt flows of each shape were not statistically 
significant and remained constant for nozzles having the same β value. A similar trend 
was found in the systemic oxygen delivery. 
In summary, there were no statistical differences between the ABG performances 
with the 4 different nozzle shapes presented in the study. 
 
Location effects 
The concentric nozzle was placed at four different locations (L= -1.5mm, 0mm, 
1.5mm and 3mm, details in Figure 4.1, subfigure E) to investigate the effects of nozzle 
location. The β value was kept constant at 0.6 and θ was set at o30 . 
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The mean values of the measured and calculated parameters are given in Figure 
4.6 and Table 4.2 to 4.3. From Figure 4.6, for the high PVR case with an L value of 3mm 
(positive value means the nozzle was protruding within the SVC), the SVC pressure 
increased from 15.0mmHg to 26.0mmHg, a dangerous level for single ventricle patients.  
For a PVR of 2.3 WU- 2m , the SVC flow rate signal drop from 0.42 LPM to 0.26 
LPM. This suggested a blockage within the SVC branch. The pulmonary blood flow 
showed a similar trend as the SVC flow. The pulmonary blood flow dropped from 0.32 
LPM to 0.26 LPM for a PVR of 2.3 WU- 2m . Oxygen delivery (OD) dropped from 3.19 
to 2.59 
2
/oml s  for a PVR of 2.3 WU-
2m .  
For a PVR of 2.3 WU- 2m , the cardiac output decreased from 1.29 LPM to 1.18 
LPM as L changed from -1.5mm to 3.0mm, due to the extra systemic resistance caused 
by the SVC blockage. The shunt flow showed an inverse decline and increased from 0.22 
LPM to 0.27 LPM for a PVR of 2.3 WU- 2m . 
In summary, a large protruding shunt (L=3.0mm here) into the SVC will partially 




Figure 4.2: Time dependent flow and pressure signals comparison within ABG circulation under 
(a) low PVR and (b) high PVR for different nozzle to shunt diameter ratios (β). Values for β = 





Table 4.2: Comparison of pressures between different nozzle designs for lower PVR (L) and High PVR 
(H) case 





55.6±0.3 5.3±0.1 4.8±0.1 4.8±0.1 




55.7±0.3 5.7±0.1 5.2±0.1 5.2±0.1 




56.0±0.3 6.3±0.1 6.0±0.1 6.1±0.1 




55.6±0.4 8.2±0.1 7.4±0.1 6.9±0.1 




55.6±0.4 8.4±0.1 8.5±0.2 8.2±0.1 




55.8±0.3 10.5±0.1 9.9±0.1 9.9±0.1 





55.4±0.3 8.5±0.1 7.3±0.1 7.1±0.1 




55.6±0.3 8.1±0.1 7.3±0.1 7.0±0.1 




55.6±0.4 8.2±0.1 7.4±0.1 6.9±0.1 




55.7±0.3 8.5±0.1 7.6±0.1 7.7±0.1 




55.4±0.3 8.7±0.1 7.7±0.1 7.7±0.1 





55.4±0.3 8.1±0.1 7.1±0.1 7.0±0.1 




55.6±0.4 8.2±0.1 7.4±0.1 6.9±0.1 




55.8±0.3 8.0±0.1 6.8±0.1 6.8±0.1 




55.2±0.3 8.1±0.1 6.7±0.1 6.8±0.1 







55.7±0.4 8.0±0.1 7.2±0.1 6.8±0.1 




55.6±0.4 8.2±0.1 7.4±0.1 6.9±0.1 




55.8±0.3 8.5±0.1 7.2±0.1 7.3±0.1 




55.6±0.3 14.3±0.1 5.8±0.1 5.7±0.1 
H 50.6±0.3 26.2±0.2 10.6±0.1 10.6±0.1 
Unit: mmHg; C, concentric; S, shape; L, location; T, tapered; P, protruding; Mean ± Standard Error 
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Table 4.3: Comparison of flow rates between different nozzle designs 
Case  Qlb Qlpa Qrpa Qsvc Qsh CO OD 







0.24 0.66±0.01 0.26±0.01 0.26±0.01 0.48±0.01 0.04±0.03 1.16±0.02 3.11±0.27 
H 0.66±0.01 0.24±0.01 0.23±0.01 0.42±0.01 0.05±0.03 1.13±0.01 2.96±0.27 
2 L 0.36 0.65±0.01 0.27±0.01 0.28±0.01 0.47±0.01 0.08±0.03 1.19±0.01 3.17±0.27 
H 0.65±0.01 0.25±0.01 0.25±0.01 0.42±0.01 0.08±0.03 1.15±0.01 2.99±0.27 
3 L 0.48 0.65±0.01 0.30±0.01 0.30±0.01 0.46±0.01 0.14±0.03 1.23±0.01 3.20±0.27 
H 0.65±0.01 0.27±0.01 0.27±0.01 0.40±0.01 0.14±0.03 1.19±0.01 3.00±0.27 
4 L 0.60 0.65±0.01 0.32±0.01 0.33±0.01 0.42±0.01 0.23±0.03 1.31±0.01 3.32±0.27 
H 0.64±0.01 0.31±0.01 0.31±0.01 0.39±0.01 0.23±0.03 1.26±0.01 3.05±0.27 
5 L 0.72 0.65±0.01 0.35±0.01 0.35±0.01 0.42±0.01 0.28±0.03 1.35±0.01 3.35±0.27 
H 0.64±0.01 0.33±0.01 0.34±0.01 0.33±0.01 0.34±0.03 1.31±0.01 2.92±0.27 
6 L 0.84 0.67±0.01 0.38±0.01 0.39±0.01 0.40±0.01 0.36±0.03 1.43±0.02 3.31±0.27 
H 0.66±0.01 0.36±0.01 0.37±0.01 0.33±0.01 0.40±0.03 1.39±0.01 3.04±0.27 







0.64±0.01 0.31±0.01 0.32±0.01 0.42±0.01 0.21±0.03 1.27±0.01 3.15±0.27 
H 0.64±0.01 0.30±0.01 0.31±0.01 0.40±0.01 0.21±0.03 1.25±0.01 3.07±0.27 
8 L 30  
0.67±0.01 0.33±0.01 0.34±0.01 0.44±0.01 0.23±0.03 1.34±0.01 3.35±0.27 
H 0.66±0.01 0.32±0.01 0.33±0.01 0.41±0.01 0.24±0.03 1.31±0.01 3.20±0.27 
4 L 40  
0.65±0.01 0.32±0.01 0.33±0.01 0.42±0.01 0.23±0.03 1.31±0.01 3.32±0.27 
H 0.64±0.01 0.31±0.01 0.31±0.01 0.39±0.01 0.23±0.03 1.26±0.01 3.05±0.27 
9 L 50  
0.65±0.01 0.31±0.01 0.31±001 0.41±0.01 0.21±0.03 1.27±0.01 3.14±0.27 
H 0.65±0.01 0.30±0.01 0.30±0.01 0.38±0.01 0.22±0.03 1.25±0.01 3.03±0.27 
10 L 60  
0.64±0.01 0.30±0.01 0.30±0.01 0.40±0.01 0.20±0.03 1.24±0.01 3.06±0.27 
H 0.65±0.01 0.29±0.01 0.29±0.01 0.38±0.01 0.20±0.03 1.23±0.01 3.00±0.27 





T 0.64±0.01 0.32±0.01 0.32±0.01 0.42±0.01 0.22±0.03 1.28±0.01 3.16±0.27 
H 0.65±0.01 0.31±0.01 0.30±0.01 0.39±0.01 0.22±0.03 1.26±0.01 3.07±0.27 
4 L C 0.65±0.01 0.32±0.01 0.33±0.01 0.42±0.01 0.23±0.03 1.31±0.01 3.32±0.27 
H 0.64±0.01 0.31±0.01 0.31±0.01 0.39±0.01 0.23±0.03 1.26±0.01 3.05±0.27 
12 L P 0.64±0.01 0.33±0.01 0.32±0.01 0.41±0.01 0.24±0.03 1.29±0.01 3.14±0.27 
H 0.65±0.01 0.32±0.01 0.30±0.01 0.39±0.01 0.23±0.03 1.27±0.01 3.08±0.27 
13 L Li 0.66±0.01 0.32±0.01 0.32±0.01 0.46±0.01 0.18±0.03 1.30±0.01 3.34±0.27 
H 0.67±0.01 0.28±0.01 0.29±0.01 0.40±0.01 0.18±0.03 1.25±0.01 3.12±0.27 




-0.15 0.65±0.01 0.32±0.01 0.32±0.01 0.42±0.01 0.22±0.03 1.29±0.01 3.19±0.27 
H 0.65±0.01 0.31±0.01 0.30±0.01 0.39±0.01 0.22±0.03 1.26±0.01 3.07±0.27 
4 L 0 0.65±0.01 0.32±0.01 0.33±0.01 0.42±0.01 0.23±0.03 1.31±0.01 3.32±0.27 
H 0.64±0.01 0.31±0.01 0.31±0.01 0.39±0.01 0.23±0.03 1.26±0.01 3.05±0.27 
15 L 15 0.65±0.01 0.33±0.01 0.33±0.01 0.42±0.01 0.24±0.03 1.31±0.01 3.21±0.27 
H 0.66±0.01 0.32±0.01 0.31±0.01 0.39±0.01 0.24±0.03 1.29±0.01 3.12±0.27 
16 L 30 0.65±0.01 0.26±0.01 0.27±0.01 0.26±0.01 0.27±0.03 1.18±0.01 2.59±0.27 
H 0.66±0.01 0.25±0.01 0.26±0.01 0.24±0.01 0.27±0.03 1.17±0.01 2.53±0.27 










































































































































































































































































































































































































































































































































































As discussed in the previous chapter, an ejector pump effect can be created within 
the ABG circulation but the effect is mild. 
In this study, there was no nozzle that produced a better ejector than another. The 
study provided useful information on the nozzle design. A nozzle to shunt diameter ratio 
around 0.60 and L = 0 seems to provide the best balance of improved pulmonary blood 
flow, oxygen delivery, and SVC pressure. A shunt angle between 30o  and 40o  is 
recommended. A nozzle design protruding into the SVC and aligned with tis axis showed 
no improvement over a nozzle contained internal to the shunt and actually increased SVC 
pressure due to the blockage by its pressure in the SVC flow path. A future goal must be 







THE ABG AORTIC COARCTATION STUDY 
 
The ABG circulation has been assessed numerically and experimentally as a 
surgical option for Stage 1 single ventricle heart disease palliation under normal 
conditions (normal PVR and no coarctation). In this section, the ABG circulation 
performance and feasibility in the presence of aortic coarctation is studied. 
The goal of this chapter is to study the effects of aortic coarctation on the global 
hemodynamics of the Assisted Bidirectional Glenn circulation. 
  
Methods 
The in vitro multi-scale system of the ABG circulation was used to study 
coarctation effects on the ABG circulation. The tests use the same generic patient LPN 
parameters and 3D anastomosis models of ABG circulation presented in the previous 
studies. Coarctation, defined as the narrowing of the aortic isthmus, was introduced as a 
narrowing of the aorta just distal to the isthmus. Severity of coarctation (details in the test 
sections) was progressively increased to assess effects. 
 
Experimental Setup  
In these tests, the mean aortic pressure was adjusted in order to maintain a 
constant cardiac output at the same baseline value while coarctation was varied. Tests 
79 
 
were run using a PVR set to a value of 2.3 WU-m2 and against at 7.0 WU-m2. The 
parametric values of the LPN model were set to the same values as reported in Table 2.1.  
 
Test Sections 
The 3-D test section of the aortic arch as used with the ABG circulation (Ligaclip 
shaped nozzle, β=0.7, θ= 40o ) was used as the base geometry in these tests. The choice 
was based on the fact that the ligaclip nozzle design produced high systemic oxygen 
delivery. A coarctation was introduced at the arch isthmus (see Figure 5.1, coarctation 
location is the region within the circle). This consisted of a smooth circular notch creating 
a local minimum in the aortic diameter, as shown in Figure 5.1. Coarctation severity was 
adjusted by manipulating the local minimum diameter. Severity is measured through the 
coarctation index (CoI), which is defined as the ratio of the local minimum (coarctation) 
diameter to the diameter of the descending aorta at diaphragm [94]. In the previous 
section, the aortic arch tested was free of coarctation. For the coarctation study, CoI was 
varied between 0.3 (very severe) to 0.9 (very mild), as indicated in Figure 5.1. A CoI = 






Cardiact output was held constant across these tests. Parameters measured were: 
pressure and flow rate at left/right pulmonary artery (LPA/RPA) and superior vena cava 
(SVC), lower body flow rate, and ascending aorta pressure. For the aortic coarctation 
study, the pressure differential across the coarctation was also measured by wall pressure 
measurements. Systemic oxygen delivery, lower body and upper body oxygen delivery 
were calculated. The details of the oxygen delivery calculation are given in Appendix H. 
 
Results 
The test results of the systems-level mean pressures and flow rates as functions of 
CoI and for two values of PVR are given in Figure 5.2 and Figure 5.3 along with 
regression lines, respectively. For either value of PVR, mean aortic pressure (MAP) 
 






remained bounded between 55.0 to 60.0 mmHg for 0.4 ≤ CoI ≤ 0.9, a range that is not 
clinically significant (a noticeable effect on daily life). For CoI < 0.4, MAP increased 
rapidly with CoI. 
For a PVR value of 7.0 WU- 2m , the left pulmonary artery pressures (upper right, 
Figure 5.2) remained nearly constant (14.5 mmHg) for 0.5 ≤ CoI ≤ 0.9. For CoI < 0.4, the 
pressure values increased rapidly towards 18.0 mmHg as CoI decreased to 0.3. For PVR 
value of 2.3 WU- 2m , the left pulmonary artery pressures (upper right, Figure 5.2) 
remained nearly constant (7.5 mmHg) for 0.5 ≤ CoI ≤ 0.9. For CoI < 0.5, the pressure 
values increased rapidly towards 10.0 mmHg as CoI decreased to 0.3. As the LPN values 
for right and left pulmonary arteries were the same, both RPA and LPA showed the same 
trend.  
The pressure within the SVC branch behaved much the same as the pressure 
within the pulmonary arteries did. For a PVR value of 7.0 WU- 2m , the SVC pressures 
(lower right, Figure 5.2) remained nearly constant (15.0 mmHg) for 0.5 ≤ CoI ≤ 0.9. For 
CoI < 0.5, the SVC pressure value increased rapidly towards 20.0 mmHg as CoI 
decreased to 0.3. For a PVR value of 2.3 WU- 2m , the SVC pressure (lower right, Figure 
5.2) remained nearly constant (9.0 mmHg) for 0.5 ≤ CoI ≤ 0.9. For CoI < 0.5, the 
pressure values increased rapidly towards 11.0 mmHg. 
The LPA and RPA flow rates (Figure 5.3) responded similarly. For a PVR value 
of 2.3 WU- 2m , the left (or right) pulmonary artery flow was nearly constant between 
0.31 LPM and 0.32 LPM for 0.5 ≤ CoI ≤ 0.9. For CoI ≤ 0.5, the pulmonary flow 
increased rapidly with CoI. For a PVR value of 7.0 WU- 2m , the pulmonary artery flow 
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was nearly constant at 0.28 LPM and 0.29 LPM for 0.5 ≤ CoI ≤ 0.9. For CoI ≤ 0.5, 
pulmonary flow increased rapidly. 
For a PVR value of 2.3 WU- 2m , the SVC flow rate (middle right, Figure 5.3) was 
nearly constant between 0.45 LPM and 0.46 LPM for 0.5 ≤ CoI ≤ 0.9. For CoI < 0.5, 
SVC flow rate increased rapidly with CoI, at CoI = 0.3, reaching a 38% percent increase 
compared with the value for 0.5 ≤ CoI ≤ 0.9. For a PVR value of 7.0 WU- 2m , the SVC 
flow rate (middle right, Figure 5.3) was nearly constant between 0.40 LPM and 0.41 
LPM for 0.5 ≤ CoI ≤ 0.9. Again, for CoI < 0.5, the SVC flow rate increased rapidly 
towards 0.58 LPM at CoI =0.3, a 45% percent increase. 
For either value of PVR, the lower body flow rate (lower right, Figure 5.3) 
remained nearly constant between 0.61 ~ 0.63 LPM for 0.5 ≤ CoI ≤ 0.9. Lower body flow 
rate decreased rapidly with CoI < 0.5, due to the extra resistance introduced by the 
coarctation. For CoI = 0.3, the lower body flow rate dropped to 0.40 LPM, a 34% percent 
decrease. 
Due to limitation of the measuring, the shunt flow rate could not be measured 
directly. Its value was calculated by the law of mass conservation (Assuming 
incompressible flow), then 
shunt SVC LPA RPAQ Q Q Q        (5–1) 
The calculated results are shown in Figure 5.3, lower left. For either value of PVR, the 
shunt flow remained nearly constant at 0.20 LPM for 0.5 ≤ CoI ≤ 0.9 and increased to 
0.28 LPM as CoI decreased to 0.3. 
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Based on these measurements, aortic coarctation did not produce clinically 
significant changes on the hemodynamics of the ABG circulation for 0.5 ≤ CoI ≤ 0.9. For 
CoI < 0.5, shunt flow rate increased and pulmonary and caval blood flows and pressures 
all increased. The systemic oxygen delivery (OD) calculation results are shown in Figure 
5.4. The OD value was remained nearly constant at around 3.3 
2
/oml s  and 3.0 2 /oml s  
for PVR values of 2.3 WU- 2m  and 7.0 WU- 2m , respectively. There were no significant 




Figure 5.2: Measured systemic mean pressure values versus CoI. ao, aorta; CoI, index of 
coarctation. lpa, left pulmonary artery; rpa, right pulmonary artery, P, pressure; svc, superior vena 
cava. PVR, pulmonary vascular resistance. Low PVR, 2.3WU-




Figure 5.3: Systemic mean flow values versus CoI. CO, Cardiac output; CoI, index of coarctation; 
IVC, inferior vena cava; LPA, left pulmonary artery, RPA, right pulmonary artery; right 
pulmonary artery, SVC, superior vena cava. Low PVR = 2.3 WU-




Figure 5.4: Systemic OD values versus CoI. CoI, index of coarctation; OD, oxygen delivery; PVR, 
pulmonary vascular resistance. Low PVR = 2.3 WU-
2m , High PVR = 7.0 WU- 2m  
 
Discussion 
This study examined the systems-level effects of coarctation on the ABG 
circulation. Aortic anatomies with mild to severe aortic coarctation were examined. For 
all measured parameters except OD, the effects of coarctation were not noticeable above 
CoI > 0.5. For CoI less than 0.5, the changes in parameter values were rapid, suggesting a 
potential need for clinical intervention. 
With constant cardiac output (CO), an increase in coarctation did not produce a 
decrease in the systemic oxygen delivery, as shown in Figure 5.4. To better understand 
the aortic coarctation effect on oxygen delivery distribution in the ABG circulation, 
consider that the upper body oxygen delivery SVCOD  and lower body oxygen delivery 
(see Appendix H for derivations) were calculated by:  
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where 
PC  and 2OV are the pulmonary oxygen concentration and oxygen consumption 
rate, respectively. The calculated oxygen delivery for the upper body and the lower 
body are given in Figure 5.5 and Figure 5.6, respectively. Under severe coarctation 
(CoI = 0.3), the upper body oxygen delivery ( SVCOD ) increased towards 2.0 2 /Oml ml  
due to the increased SVC blood flow rate. However the lower body oxygen delivery 
( LBOD ) decreased towards 1.3 2 /Oml ml due to a large decrease in the lower body flow 
rate. This presented a problematic situation in the distribution of oxygen. Low LBOD
will lead to insufficient oxygen content in the lower body, which could lead to 
ulceration and other oxygen insufficiency related diseases. So which systemic OD did 
not appear affected by severe CoI (Fig 5.4), a closer look at the distribution of systemic 
OD shows measureable changes as CoI < 0.5, consistent with other measured 





Figure 5.5: Calculated upper body oxygen delivery values versus CoI. CoI, index of coarctation; 
OD, oxygen delivery; PVR, pulmonary vascular resistance. 
 
 
Figure 5.6: Calculated lower body oxygen delivery values versus CoI. CoI, index of coarctation; 
OD, oxygen delivery; PVR, pulmonary vascular resistance. 
 
Pressure Drop Analysis 
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The pressure drop across the coarctation is an important parameter. The measured 
pressure drop across the coarctation of the ABG circulation for the PVR value of 2.3 
WU- 2m  and 7.0 WU- 2m  is presented in Figure 5.7. The pressure drop increased as the 
CoI decreased. The pressure drop increased measurably for CoI < 0.5. The resulting 
Figure 5.7 matched well to the results reported by Hang [48] in an aortic coarctation 
study of the Norwood circulation using an similar in vitro test loop. Similar results of 
pressure drop across the coarctation of a real Norwood patient were also reported by 
Biglino et al. [67]. Although the ABG circulation has a different physiology structure 
compared with the Norwood circulation, the structural difference does not have an 
influence on the lower body branch. Clinically, a final pressure drop across the aortic arc 
coarctation of less than 10.0 mmHg is considered a success [47] in a coarctation 
intervention. From this study, at CoI = 0.5, the pressure drop across the coarctation was 




Figure 5.7: Measured wall pressure drop across coarctation versus CoI. CoI, index of coarctation. 
Measured results of the flow distribution showed that the inferior vena cava flow 
( IVCQ ) was highly sensitive to coarctation. This finding matches well with the 
observations made by Biglino et al.[67]. The variation of lower body flow rate influenced 
another important parameter: the ratio of pulmonary flow rate to systemic flow rate ratio 
(Qp/Qs). The measured Qp/Qs as a function of CoI is shown in Figure 5.8 for either value 
of PVR. As CoI decreased from 0.9 to 0.3, Qp/Qs increased from 0.58 to 0.88. The 
reason was that the coarctation decreased the lower body flow rate and increased the 




Figure 5.8: Calculated Qp/Qs ratio versus CoI. CoI, index of coarctation; Qp, pulmonary flow 
rate; Qs, systemic flow rate. 
The CO was held constant in this coarctation study. Biglino et al. [67] and Hang 
[48] used the constant cardiac output as the control input parameter, while Corsini et al. 
[95] used body surface area (BSA), PVR and SVR as the control input parameters for a 
CFD coarctation study. Several observations in Corsini et al. [95] are different from the 
findings in this study. For example, they reported that the CO and systemic oxygen 
delivery decreased (almost constant in this study) as CoI decreased. However, this current 
study found OD to be nearly constant with varying CoI. The question of how to choose 
the control input for a single ventricular circulation modeling to simulate the natural 




One limitation of this study is that only one simple aortic coarctation morphology 
was tested. Previous studies found that coarcation morphologies had effects on the 
hemodynamics of the Norwood circulations [95, 67, 48]. Future studies should 






RESPIRATION EFFECTS ON STAGE 2 CIRCULATION 
 
In this chapter, a respiration model is added to the in vitro Stage 2 circulation 
model previous described. The system is verified and validated by comparing the 
measured hemodynamic parameters with clinical data or analytical predictions. The 




A respiration model previously validated by Vukicevic [74] is utilized in the 
Stage 2 MCS system. The schematic of the system and the photograph of the 




Figure 6.1: Reduced lumped domain network model used for the Stage 2 mock 
circulatory system with respiration. BCPA, Bidirectional Cavopulmonary Anastomosis; 
C, compliance; lb, lower body; lld, left lung distal; llp, left lung proximal; lp, left lung; 
lpa, , left pulmonary artery; lpv, left pulmonary vein; P, pressure; Q, flow rate; R, resistance; rld, 
right lung distal; rlp, right lung proximal; rp, right pulmonary; rpa, right pulmonary artery; rpv, 
right pulmonary vein; svc, superior vena cava; ub, upper body; ubd, upper body distal; ubp, upper 





Pulmonary Compliance Elements 
The pulmonary compliance elements were made of two elastic tubes; each tube 
was attached inline to a separate pulmonary artery branch, and both housed within a 
single sealed air chamber, acting as the thoracic cavity. The elastic tubes were adapted 
from pediatric respiration balloons. A rigid tube placed over each elastic tube restricts 
expansion and was the means to adjust its compliance. Figure 6.3 shows another 
pulmonary compliance chamber similar to the one used here. The method to tune and 
calibrate the compliance value of the pulmonary compliance is given in Appendix C. 
 
Figure 6.2: Photograph of Glenn circulation MCS: 1, Head tank; 2, Aorta compliance element; 3, 
SVC compliance element; 4, Berlin heart VAD; 5, SVC resistance element; 6, SVC flow meter; 7 
and 9, RPA and LPA  resistance elements; 8, Test section; 10, pressure transducers; 11, pulmonary 
compliance element. LB, lower body; LPA, left pulmonary artery; RPA, right pulmonary artery; 





Figure 6.3: Photograph of the pulmonary compliance used in the lab. 
 
The Respiration Model 
The act of breathing creates a vacuum pressure in the thoracic cavity during 
inspiration, relaxing to slightly negative pressure during expiration and rest. Due to the 
lack of a valve in the Glenn anastomosis in single ventricle patients, respiration affects 
the motion of blood flow returning through the pulmonary circulation towards the heart. 
The respiratory amplitude of thoracic cavity vacuum is dependent upon the age. Under 
resting conditions, it varies from a nominal amplitude of 2 mmHg for an infant to 5 
mmHg for an adult [96]. A magnitude ranging from -2 to -6 mmHg is applied in the 
Stage 2 circulation MCS. 
Time-dependent respiration pressure was produced using a programmable 
proportional pneumatic regulator (ITV1009, SMC Corp, Noblesville, Inc.) and a solenoid 
valve (Model: 225B-111CAAA, MAC Valve, Dundee, MI, USA)  responding to a 
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computer controlled voltage waveform to control alternating vacuum pressure and 
atmospheric pressure. The schematic of the system is given in Figure 6.4. The control 
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Here,
thA is the amplitude of −4 mm Hg for the thoracic pressures. The ratio of the 
activation function period, at , to respiration cycle period, rt  , was 0.375 in all tests. 
Unless otherwise stated, the respiration rate was 30 bpm (
rt   = 2.0 s). restP  
was set to 
atmospheric pressure. The control signal of pressure waveform and physical realization 
within the pulmonary compliance chamber is shown in Figure 6.5. 
 




Figure 6.5: Control signal and physical realization of time dependent respiration amplitude. 
 
Patient Selection and LPN Parameters  
No previous in vitro MCS study has been reported for a Stage 2 Glenn circulation 
with respiration. In this research, two Stage 2 cases were studied, including two different 
surgical time points (TP4: time point 4, which corresponds to just after the Stage 2 
surgery; TP5: time point 5, which corresponds to just before the Stage 3 Fontan surgery) 
for the patient designated here as UM2 (UM, University of Michigan), where the 
acronym refers to the patient’s clinical center and the numerical value identifies the 
patient’s record as discussed in Chapter 2. The specific parametric values used are listed 





Table 6.1: LP elemental values for Stage 2 respiration study 
Parameters Unit UM2_TP4 
Pao mmHg 53 
Pat mmHg 2.5 
Rlb mmHg.s/ml 6.67±0.21 
Rubd mmHg.s/ml 3.24±0.08 
Rubp mmHg.s/ml 0.16±0.01 
Cup ml/mmHg 0.24±0.01 
Rrlp mmHg.s/ml 0.49±0.02 
Rrld mmHg.s/ml 1.21±0.06 
Crl ml/mmHg 0.63±0.04 
Rllp mmHg.s/ml 0.11±0.01 
Rlld mmHg.s/ml 2.80±0.08 
Cll ml/mmHg 0.36±0.04 
Cao ml/mmHg 0.20±0.01 
HB times/min 120 
RR times/min 30 
 
C, Compliance; LB, Lower body; LL, Left lung; LLD, Left lung distal; LLP, Left Lung Proximal; 
LP, Lumped parameter; LPN, Lumped parameter network; R, Resistance; RL, Right lung; RLD，
Right lung distal; RLP, Right lung proximal; RR, Respiration rate; UP, Upper body; UPD, Upper 
body distal; UPP, Upper body proximal. TP4, Time point 4, just post Glenn surgery; 
 
Results 
 Case UM2_TP4: Verification of the System 
This case presents a verification of the Stage 2 model with respiration by 
comparing the experimental results with analytical predictions for patient UM2 at time 




Experimentally measured flow rates, pressures and corresponding analytical 
results over one respiration period are shown in Figure 6.6 – 6.7. The agreement between 
experimental and analytical pressure and flow rate is reasonable with satisfactory 
amplitude and phase matching (0.60 < 2R  < 0.96, p > 0.05).  
The experimental SVC flow rate matched well with the analytical predictions 
with satisfactory amplitude and phase matching ( 2R  = 0.89, p > 0.05). The calculated 
was 6%, demonstrating the model is a reasonable match with the analytical model. 
The measured RPA flow rate matched well with the analytical predictions with 
satisfactory amplitude and phase matching ( 2R  = 0.64, p > 0.05). The calculated  was < 
5%, demonstrating reasonable agreement.  
The LPA flow rate signal showed more pulsatility in response to both heartbeat 
and respiration, because the left lung was set to a smaller proximal resistance value, 
matching clinical measurement. The measured LPA flow rate matched well with the 
analytical predictions, with satisfactory amplitude and phase matching ( 2R  = 0.84, p > 
0.05). The calculated  of 10% shows reasonable agreement, and the rounding of 
relatively sharp peaks seen in the analytical reference probably resulted from inertance in 
the MCS.  
The experimental lower body flow ranged from 0.40 to 0.58 LPM, which is 
smaller than the analytical range 0.32 to 0.60 LPM. However, the lower body flow rate 
was only controlled by a single resistance element, and its time based behavior was not 
intended to be modeled, just its mean value. So the mismatch between the two models of 
the time-based lower body flow rate is acceptable.  
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Three pressures pressure waveforms were investigated: (1) aorta pressure, the 
input signal to the system; (2) bidirectional cava pulmonary anastomosis (BCPA) 
pressure; and (3) respiration pressure.  
As seen in Figure 6.7, measured pulsatile aortic pressure matched well with the 
analytical one with satisfactory amplitude and phase matching ( 2R  = 0.90, p > 0.05). The 
calculated   was < 10%. The measured respiration pressure matched well with the 
control analytical signal ( 2R  = 0.65, p > 0.05). The calculated   was < 5%. 
Mean values of the (BCPA) pressures match well (p > 0.05) between the 
analytical prediction and experimental measurement. The pulsatility of experimental 
BCPA pressure is slightly higher than that of the analytical one ( 2R  = 0.65,   = 8%), 
and there is the visible lag of the peak. This may be caused by a mismatch of the 
compliance values and/or inertance effects not included in the analytical model.  
In summary, the agreement between experimental and analytical pressures and 
flow rates are quite reasonable with satisfactory amplitude and phase matching (0.78 < 
2R  < 0.90, p > 0.05 and   < 10%). The results show acceptable functionality of the in 




Figure 6.6: Comparison between analytical and experimental flow rate for UM2, time point 4. 
Exp, experimental;  Sim, simulation; LB, lower body; LPA, left pulmonary artery; RPA, right 





Figure 6.7: Comparison between analytical and experimental pressures for UM2, time point 4. 
Exp, experimental; Sim, simulation; BCPA, bidirectional cava pulmonary anastomosis. 
 
Case UM2-TP5: Validation of the Respiration System 
In most of the literature, clinical data in Stage 2 patients are only measured over 
one heartbeat, or heartbeat-gated. So, it is difficult to validate a respiration model using 
clinical data. Here we have two rare sets of clinical pressures (LPA and SVC) of patient 
UM2 at time point 5, recorded over one full respiration period and used to validate the 
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MCS. The comparison between the experimental and clinical LPA pressure and SVC 
pressure over one respiration period are given in Figure 6.8-6.9, respectively.  
The experimental LPA pressure matched well with the clinical measurement, with 
satisfactory amplitude and phase matching ( 2R  = 0.62, p > 0.05). The calculated   was 
7.6%. The experimental SVC pressure matched well with the clinical SVC pressure with 
satisfactory amplitude (p > 0.05) and phase matching ( 2R  = 0.68) and  was < 5%. 
These two well-reproduced signals demonstrate that the model is able to recapitulate the 
clinical signals with respiration. The high frequency pulsatility and noise in the clinical 
signals might be either physiological in nature or measurement noise, there is insufficient 
information to determine the cause. 
 
Figure 6.8: Comparison between clinical and experimental LPA pressures for UM2, time point 5. 






Figure 6.9: Comparison between clinical and experimental SVC pressures for UM2, time point 5. 
CLI, clinical; EXP, experimental; SVC, superior vena cava. 
 
Discussion 
This chapter introduced and verified the Stage 2 circulation with respiration 
model. Previous studies on Stage 2 circulation have only investigated the hemodynamics 
over one heartbeat. From the results in this chapter, the signals show a clear interaction 
between respiration and heartbeat. The impact of this time-based information on local 
hemodynamics has not been demonstrated previously in a model without respiration. 
The pulsatility of flow rate and pressure is known to be beneficial for the growth 
of pulmonary vasculature [91]. Further, in a clinical Stage 2 study, SVC retrograde blood 
flow was documented to occur but not fully understood [97].  
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The Stage 2 MCS with respiration model presented offers a way to study these 
effects. If respiration effects affect flow pulsatility, then they will influence 
hemodynamics values, such as wall shear stress, directly. Respiration modeling provides 
more correct boundary conditions for the test section. Respiration is capacitive coupled, 
so it does not directly affect mean pressure or flows, but it does increase the RMS value 
of flow. Increased RMS can in fact increase the mean pressure drop through a nonlinear 
resistance, such as in the ABG shunt, with subsequent changes throughout the system. 
Also for three dimensional velocity field reconstruction, ignoring respiration will 
accumulate error [98]. 
In summary, the ability to impose respiration into an experimental model of the 
Stage 2 circulation has been verified by direct comparison to an LPN analytical model 
with respiration. Then the system was validated against rare clinical signals obtained over 





SUMMARIES AND CONCLUSIONS 
Summaries and Conclusions 
An in vitro multi-scale model of the Norwood with mBTS and Glenn (BDG) 
circulations was proposed and built. Generic and patient-specific conditions were 
achieved and the system was verified and validated by comparing experimental results 
with numerical or/with clinical data. Resulting parameters measured were: pressure and 
flow rate at left/right pulmonary artery and superior vena cava (SVC). Systemic oxygen 
delivery (OD) was calculated. Experimental results of the time based pressures and flows 
demonstrated the same form as the clinical data or simulation predictions. The statistical 
analysis and frequency analysis shows good match (0.62 < 2R  <0.95, p > 0.05; r.m.s 
error,  < 10%) between the in vitro MCS measurements, clinical data and numerical 
predictions. The hypothesis that it is possible to model the first and second stage 
palliation circulations using multi-scale in vitro circulation models was validated. 
The validated in vitro model was used to recapitulate prior numerical simulation 
results while demonstrating the practical implementation of a novel approach to a first 
stage palliation of univentricular physiology called the ABG concept. Comparisons of the 
major experimental and numerical mean flow results were not significantly different (p > 
0.05) and mean pressure differences were within 1.2 mmHg (p > 0.05). The phase also 
matched well (0.62< 2R  <0.95,   < 10%), lending confidence in the numerical model. 




The experimental results found that the ABG circulation provides an increase of 
30–38% in pulmonary flow with a 2.0~3.7 mmHg increase in SVC pressure compared to 
the Glenn circulation and a 4~14% higher systemic OD than either the Norwood or the 
Glenn circulations. While the concept of the ABG circulation and the application remains 
hypothetical, the ABG circulation would have certain advantages over current palliation 
strategies. Using the ABG circulation in place of the Norwood circulation (such as the 
mBTS) as the initial palliation in neonates would reduce the number of surgeries in the 
Fontan circulation conversion from 3 to 2. While doing so, the ABG circulation could 
provide a more reliable source of pulmonary blood flow with reduced risk from 
thrombosis and cyanosis. The increased pulmonary blood flow and systemic oxygen 
delivery would allow for improved stress tolerance and reduce baseline cyanosis than the 
Norwood circulation. The ABG adds a component of pulsatility to the pulmonary blood 
flow, which could potentially improve pulmonary vascular development and exercise 
tolerance. 
A study was conducted to examine the ejector pump effect used in the ABG 
circulation. Results show that the nozzle placed within the ABG shunt acted not only as a 
resistance element, but also produced an ejector pump effect. The hypothesis that an 
ejector pump advantage can be adopted in a superior cavo-pulmonary circulation, where 
the low-energy pulmonary blood flow can be assisted by an additional source of high 
energy flow from the systemic circulation was validated. But the eject pump effect was 
not strong enough to reduce the SVC pressure by more than 2.0 mmHg using the nozzle 
designs presented in the study.  
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The parametric study of the nozzle used in the ABG showed that the nozzle 
diameter to shunt diameter ratio β is the most important parameter when determining the 
ABG performance. A good choice on β fell between 0.48 and 0.72, which produced the 
highest systemic oxygen delivery without increasing SVC pressure to dangerous levels. A 
shunt angle between 30o  and 40o  show a slight improvement on pulmonary blood flow 
and systemic oxygen delivery over other angles. Nozzle design did not appear to have 
much influence on the systems-level hemodynamics, at least for the designs tested. 
However, nozzle placement did. Best results were obtained for a nozzle internal to the 
shunt as close to the SVC-shunt anastomosis as possible. Placing the nozzle within the 
SVC showed a blockage effect of higher SVC pressure with no other benefits. 
As coarctation is common to initial palliation of single ventricle patients, the in 
vitro MCS was used to study the effects on the performance of the ABG circulation. A 
coarctation index (CoI) was used as a measure of coarctation severity. CoI variation of 
0.3 to 0.9 was used in the study. Results demonstrated severe coarctaiton would decrease 
lower body flow and increase SVC and shunt flow. While total systemic oxygen delivery 
was not sensitive to coarctation, severe CoI produced measureable effects on oxygen 
delivery distribution to the upper body and the lower body. The results suggested that 
significant hemodynamic changes occurred for CoI < 0.5, suggesting a need for surgical 
intervention. 
A Stage 2 circulation model with respiration effects was built and verified by 
comparing experimental signals (flow rates and pressures) with clinical data and/or 
numerical predictions with one respiration period (0.65 <  < 0.92, p > 0.05,  < 10%). 2R 
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Comparison between the respiration case and no respiration base case showed that 
respiration should be included to recapitulate clinical data.  
In summary, the ABG could be used as a Stage 1 palliation option for single 
ventricle heart disease patients. It could provide more stable pulmonary blood flow 
source and relieve the ventricle load compared with the Norwood circulation. But due to 




Although there is satisfactory matching between the experimental results, LPN 
analytical results, multi-scale numerical results, and clinical data, there are limitations 
that should be clear:  
(1): The data required for tuning of the circuit sometimes must rely on generic 
information taken from literature.  In the case of the Stage 2, time point 4 validation, the 
patient data was taken at a time point just prior to the Stage 3 surgery, not after the Stage 
2. This presents a problem in model validation as there is usually no post-surgical clinical 
data to validate the system’s functionality for the time point just after the surgery. 
 (2): The 3D model geometry used in the experimental models has been simplified 
in some respects. For instance, in the in vitro study, the coronary arteries were not 
modeled and the multi-generational daughter pulmonary artery branches of the lungs 
were not modeled. 
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(3): The test section vessel walls were rigid, just as they were in the numerical 
models used for comparison. However, a lumped aortic compliance was used to 
accommodate for the rigid aortic walls resulting in the clinically realistic aortic pressure 
waveforms. 
 (4): Gravity was not accounted for the models. Tests assumed the patient to be in 
the supine position under resting conditions. The MCS can be tuned for exercise 
conditions and adjusted to represent upright stature, but these were not tested here. 
(5): The ABG concept was only assessed globally by comparing the pressures and 
flow rates. Future work should investigate the local parameters to assess the ABG 
comprehensively. Suggested parameters include wall shear stress (WSS), energy losses 










Appendix A: Thevenin Theory to Reduce a Full Model 
This section describes how to reduce one LPN branch of the circulation into a 
reduced LPN model. To do this, we apply least-squares matching of the impedance 
spectrum from Thevenin equivalent circuit analysis. Given an arbitrarily complex 
network of resistances, compliances, inertances, and pressure sources, the Thevenin 
theory says that the behavior of the network with respect to a certain outlet can be fully 
described by one source pressure, and the outlet impedance spectrum. A simple R-C-R 
block to most-closely approximate the impedance spectrum was designed. It connects its 
outlet to an inlet to the test section, and will most-accurately reproduce the sensitivity of 
the full model to both steady and unsteady flow dynamics in the test section. 
Here an example of using the method to reduce the SVC branch from the patient-
specific model of patient MUSC2 at Time point 4 (post-Glenn surgery examination) was 
given. Figure A.1 depicts the original full SVC branch. The values of each element are 
listed in Table A.1. The target reduced branch is shown in Figure A.2. The described 
method is used to determine the equivalent values for the reduced branch design. 
 




Figure A.2: The targeted reduced R-C-R block from the full SVC branch. 
Table A.1: Parameters of the full SVC branch shown in Figure A.1 
Parameter Value 
UBAR   2.01 mmHg.s/ml 
UBAL   6.26E-04mHg*
2 2/ mls   
UBC   0.57 ml/mmHg 
UBVR   5.87 mmHg.s/ml 
SVCC   0.26 ml/mmHg 
SVCR   0.54 mmHg.s/ml 
 
The ordinary differential equations (ODEs) for the SVC branch shown in Figure 
A.1 are listed below: 
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AOP  is the aorta pressure.  
According to Kirchhoff’s circuit law,  
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where 2s f , f is the frequency.  
The Thevenin pressure was obtained with the assumption that the SVC circuit is 
open (no out flow). This assumption is equivalent to the clinical method to measure the 
wedge pressure, which was measured using catheter tip ‘wedged’ in the tapering branch. 
So 
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The Thevenin pressure SVC OPENP   can be obtained by solving (A-5) and (A-6): 
1/(R +s*L )+s*C +1/R -1/R P /(R +s L )
=
-1/R 1/R +s*C 0
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The Thevenin flow rate was calculated with the assumption that the SVC branch 
was close or connected to the ground (0mmHg pressure) (also called “short circuit”). The 
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The final impedance of the branch can be calculated as 
      1
( ) /SVC OPEN SVC SCZ s P Q                                                    (A-8) 
Applying the same method, the outlet impedance of a reduced R-C-R block, as 
shown in Figure A.2, for a given frequency f can be expressed as a single equation: 
           
2
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Figure A.3 shows the complex impedance spectrum for the full model (blue line), 
and the reduced model (red line). At zero frequency (steady flow), the impedance is real-
valued, equal to the total resistance, 8.42 mmHg*s/ml. This is one constraint on the 
design of the reduced model. Two free variables remain, the values of C and ubpR . The 
system will be driven by the heartbeat, and therefore it is most important to match the 
impedance at the fundamental frequency of the heartbeat, and its first three harmonics. 
The complex impedance at those frequencies is marked with circles in Figure A.3. The 
values of C and ubpR  were optimized in an iterative search, minimizing the sum of 
squares of impedance errors at those chosen frequencies, and finally the value of ubpR  
was calculated from ubpR . The final reduced design is ubdR  
=7.86 mmHg*s/ml, ubC  = 
0.26 ml/mmHg, ubpR =0.56 mmHg*s/ml, and the impedance match is excellent at the four 




Figure A.3: Impedance spectrum comparison between the two models. For frequencies f > 0 the 
imaginary component of the spectrum is negative, indicating that pulsatile flow leads pressure as 
expected for a compliant system. 
 
Appendix B: Resistance Calibration 
The calibration system schematic for calibrating resistance element is given in 
Figure B.1. The height difference of two head tanks was used to drive a flow producing 
the pressure differential across the resistance element. Resistance was calculated by the 
measured pressure differential and flow rate. For a ball valve, the resistance is not 
constant and is a function of flow rate. So it was important to calibrate the resistance 
under the operational flow rate. Laminar resistors using capillary glass was made 
following the method introduced by Kung and Taylor [99]. Figure B.1 to Figure B.3 are 
the schematic of the test table and details of the resistance element construction. Glass 
capillaries with different outer diameters, inner diameters and lengths (Sutter Instrument; 
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One Digital Drive, Novato, CA 94949, USA) were used to produce different resistance 
values. Resistance was preestimated by: 
4
8







where µ is the dynamic viscosity of fluid, l  is the length of the glass capillaries, N is the 
number of capillaries inserted in the tube and r  is the inner radius of the capillary glass. 
Though outer radius is not shown in the equation, its value and radius of the tube 
determine N. The relationship between the N, tube diameter and capillary glass outer 
diameter were established using the application found at: http://hydra.nat.uni-
magdeburg.de/packing/cci/cci.html. The predicted values were used as a starting point for 
a laminar resistance element design. Small adjustments were made by blocking some 






Figure B.2: Detail A about the resistance element component 
 
Figure B.3: Detail B for components in resistance element connector. 
Figure B.1: Schematic of the resistance element calibration system. 
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Appendix C: Compliance Calibration 
Compliance values were confirmed by calibration, which measured the volume 
change associated with an applied pressure change to the compliance element. All the 
compliances in the system were grounded to atmosphere, except the respiration 
compliance, which was grounded to the respiration pressure. The compliances grounded 
to the atmosphere respond to the pressure variation of the connected branch, whereas a 
compliance grounded to the respiration pressure responds to an applied respiration 
pressure. The respiration pressure itself was applied to the sealed air chamber so as to act 
on the exterior surface of the compliance element. 
The calibration process for the compliance value involved varying the pressure in 
the liquid side and measuring the volume change of the liquid. The operable pressure 
range was selected based on the appropriate pressures the compliance was associated 
with.  
The setup of the compliance value tuning or calibration system was introduced by 
Chiulli [100] and is shown in Figure C.1. In practice, the air chamber is connected to a 
tube, which is filled with water. Another end of the tube is left open to air. The tube is 




Figure C.1: Compliance tuning system [90] 
At the initial state, the fluid heights in both legs of the U-tube (Figure C.1) were 
equal. The open side tube was next raised to a height. The pressure change applied to the 
chamber equals to the difference in height between the two water columns. The volume 
change was estimated by the change in the fluid’s height on the closed side. Several 
pressure and volume data points were obtained by lifting the tube. A pressure change 
versus volume change (P-V) diagram, whose slope equals to the compliance, was plotted 
to calculate the compliance.  
As an example, Table C.1 gives the measured data for one compliance calibration 
and Figure C.2 is the corresponding P-V curve constructed from it. Compliance remains 






Table C.1: Spreadsheet of compliance calibration procedures 





1 22.50 0.00 0.00 0.00 0.00 
2 28.10 5.60 20.00 4.12 2.62 
3 31.10 8.60 30.00 6.32 3.89 
4 34.10 11.60 40.00 8.53 5.16 
5 37.00 14.00 50.00 10.29 6.54 
6 40.10 17.60 60.00 12.94 7.71 
z, water level reading; z , change of water height from starting point; h  , change of hose 
height; p , pressure change; v  , volume change. 
   
 




Appendix D: Uncertainty Analysis 
In this section, the methods used to calculate the uncertainty for the LPN 
parameters (R, C values), measured results (pressure and flow rates) and calculated 
parameter (oxygen delivery) presented in this dissertation are discussed. 
Errors are divided into two categories: systemic error and random error [101]. The 
systemic errors shift the sample mean away from the true mean by a fixed but unknown 
amount, and within a sample of many measurements, the random errors bring about a 
distribution of measured values about the sample mean. The approach to propagate the 
uncertainties used in this dissertation is described by Figliola and Beasley [101]. 
Elemental systemic errors, systemic standard uncertainties are propagated as:  
1
2( ( ))     (D-1)kkb b   
where   is the sensitivity factor. In a similar manner, random standard uncertainties are 
propagated as  
1
2( ( ))     (D-2)kks s   
 
Uncertainty estimation for pressure and flow rate measurements 
Sources of uncertainties in the pressure and flow rate results include instrument 
error, zero set-point error, data-acquisition error, and the statistical standard error from 
measurement. Instrument errors are determined by systematic uncertainty according to 
manufacturer’s manual statement of error. The instrument error is specified as 0.5% of 
the instrument reading for both flow and pressure measurements. Zero set-point error, 
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which is the difference between the tuned zero point and the real zero point, is 0.10 
mmHg and 0.01 LPM for pressure measurement and flow rate measurement, respectively, 
in our experience with these instruments. Data-acquisition error is defined as the error 
produced during the measurement process. The value is based on the voltage range of the 







  (D–3) 
where VR is the voltage range of the sensors and n is the number of bits of the DAQ 
board (16 in the National Instruments USB-6211). 
The statistical standard error (or standard error of the mean: SEM), was calculated 
by: 






where xs  is the sample standard deviation, and N is the number of samples. In this 
dissertation, a data set of 20 mean values was used to calculate the standard error.  
Based on the introduction above on each type of uncertainty distribution, a sample 
of uncertainty calculation details for one flow and one pressure measurement in the ABG 





















aoP (mmHg) 54.1 0.27 0.10 0.004 0.50 0.58 1.1% 
CO (LPM) 1.05 0.005 0.01 0.003 0.02 0.023 2.2% 
Uncertainty estimation for resistance and compliance value 
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This treatment assumes that P1 and P2 are measured by independent channels, as was 
often the case, so that there is no correlation of the instrument uncertainty between them. 
The compliance of a trapped-air style compliance element (or “windkessel,” as in 





 .  The uncertainty estimation for the windkessel compliance is given by: 
2 2
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An example of uncertainty estimation for R, C value used in the ABG circulation 
test, high PVR was given in Table D.2 and Table D.3, respectively. For R calculation, Q 
was set at 0.60 LPM, 
1P  and 2P  were set at 54.0 mmHg and 2.0 mmHg, respectively. For 
C uncertainty calculation, V is 154.1 ml and Pabs is 760 mmHg. A relative uncertainty of 
1%, namely 1.5ml and 6.7 mmHg, were utilized in the calculations. 




















lbR 5.48 0.52 0.28 0.09 0.54 0.09 0.20 0.16 2.9% 












lbC 0.23 0.0015 1.5 0.00034 6.7 0.0032 1.4% 
Oxygen delivery Uncertainty calculation 
Systemic oxygen delivery (OD) was calculated by measured flow rates and 
referred clinical values: 
2
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pC stands for oxygen concentration in pulmonary, 2oV stands for total oxygen
consumption and  
2 2.
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An example of OD uncertainty estimation is given in Table D.4. The values of pC
and 
2o
V were set to 0.22
2
/oml ml and 0.874 2 /oml s as reported in a previous study[26] and 
was quite constant, a reasonable uncertainty estimation for these two clinical data were 5% 
(0.011
2
/oml ml for PC   and 0.0437 2 /oml s for 2oV ).  
Table D.4: An example (ABG, high PVR) to calculate the uncertainty estimation for OD 
































OD 3.09 0.175 0.47 0.083 0.47 17.7 0.011 0.98 0.0437 0.21 6.8% 
Appendix E: Calculation of Coefficient of Determination 
In a linear regression model 0 1
ˆ ˆŷ =  + x  , coefficient of determination ( 2R ) is 
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where 
iY is the real dependent variable corresponding to the thi  independent variable ix , 









  (E–3) 
where iY  is the estimated dependent variable based on the linear regression model. The 









  (E–4) 
In this dissertation, experimental results and clinical data or signals from the 
numerical model were compared point-to-point at corresponding times using linear 
regression (y = x) from which a coefficient of determination ( 2R ) was calculated. The
closer to unit in 2R , the better linear association between x and y, suggesting the better 
match between the experimental results and clinical measurements or numerical 
predictions. 
Appendix F: t-test and p value Calculation 
In this dissertation, an unpaired Student’s t-test was used to compare the mean 
values between different models, such as experimental results to clinical measurements or 
experimental results to numerical predictions. A p-value of 0.05 or less (p < 0.05) was 
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considered to indicate a statistically significant difference between the two mean values. 
Values were determined using Mablab. 
The unpaired student’s t test tests the null hypothesis that the population means 
related to two independent, random samples from an approximately normal distribution 


































where 1x and 2x are the sample means, 
2s is the sample variance, 1n and 2n are the 
sample sizes and t is the t-value with freedom 1 2 2n n  . 
Appendix G: RMS-Error Calculation 
Root-mean-square (r.m.s) error is the root-sum-square of the deviation between 
two values observed at the same time point in a time-based signal. The deviations are 
summed over the full heartbeat. Hence the experimental signal is compared to either the 
numerical signal or clinical signal. The use of rms error is an excellent general purpose 









r m s y y
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        (G-1) 
where iy is the observed value (in this research, the observed value is the clinical data) 
and 
iy is the predicted value (in this research, the predicted value is the experimental 
data). The rms error reported in this document is normalized by the mean values as: 
 error/y    (G-2)rms 
Appendix H: Oxygen Delivery (OD) Calculation 
Oxygen delivery within the MCS was not measured but calculated based on flow 
rates to the various branches. Let
2
Vo 2.Vlb o , 2.oVub represent total oxygen consumption, 
lower body oxygen consumption and upper body oxygen consumption, CP  , Cao  , Civc  ,












V (1 )Vub o or  (H-2) 
Oxygen delivery (OD) is the product of oxygen concentration in aorta and 
systemic flow rate by definition: 
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ao sOD C Q (H-3) 
Applying the conservation of oxygen equation [29]: 
2.
V ( )ub o ub ao svcQ C C  (H-4) 








    (H-5) 
We assume r equals 0.5 for most of the cases. The pC and 2Vo are set to 0.22 
2
mL /o mL and 0.874 2mL / so on the basis of generic clinic data obtained from
catheterization exams and the fact that pulmonary veins has a 98% oxygen saturation [26]. 
a) For the mBTS circulation:
    
2
( )o p p aoV Q C C       (H-6) 
and combined with equation H-3, we can get: 
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   (H-7) 
b) In the Glenn circulation:
2
( )o p p svcV Q C C   (H-8) 
Also, as in the Glenn circulation, the SVC in connected directly to the pulmonary 
circulation, so svc pQ Q . From equation H-5 and H-8,  
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Inserting equation H-9 into equation H-3, the oxygen delivery is 
        
2





   (H-10) 
c) The ABG circulation is a combination of the Glenn and mBTS
circulations. The oxygen consumption is found by 
2
( )( ) ( )o p ub p ao ub p svcV Q Q C C Q C C      (H-11) 
Using equation H-5 and H-3, we get the same expression for oxygen delivery as 
in the Glenn circulation: 
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   (H-12) 
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